Novel compound and virus detection reagent, and virus detection method using the same

Novel sialic acid derivative compounds provide a means to specifically detect and differentiate influenza A and B viruses and mumps virus by producing a fluorescent signal, addressing the lack of easy clinical tests and labor-intensive isolation methods for these viruses.

JP2024159617APending Publication Date: 2024-11-08UNIV OF SHIZUOKA +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024069441
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-04-28
Filing Date
2024-04-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Current diagnostic methods for influenza, mumps, and human parainfluenza viruses lack easy-to-use clinical tests and struggle to differentiate between virus types, requiring labor-intensive isolation and culture techniques.

Method used

Development of novel sialic acid derivative compounds represented by formulas (I), (II), and (III) that act as sialidase substrates, allowing for specific detection and differentiation of influenza A and B viruses, as well as mumps virus, by producing a fluorescent signal.

Benefits of technology

Enables easy identification and differentiation of virus species through histochemical fluorescence imaging, facilitating rapid isolation and culture of virus strains from clinical specimens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024159617000029
    Figure 2024159617000029
  • Figure 2024159617000030
    Figure 2024159617000030
  • Figure 2024159617000031
    Figure 2024159617000031
Patent Text Reader

Abstract

To provide a detection reagent that can differentiate and detect virus types that express sialidase.SOLUTION: The present invention provides compounds represented by formula (I), formula (III) or the like, or salts thereof, or solvates thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to novel compounds represented by formula (I), formula (II) and formula (III) and reagents for detecting viruses or viral sialidases, which contain the compounds. [Background technology]

[0002] Influenza virus, mumps virus, and human parainfluenza virus are highly contagious human pathogens. For influenza virus, diagnosis is performed using antigen test kits, but for mumps virus and human parainfluenza virus, no test kits that can be easily used in clinical practice have been introduced at present.

[0003] In addition, in order to grasp the prevalence of this type of virus, public health testing institutions isolate and culture the virus from clinical specimens and identify the virus. When isolating and culturing the virus, the morphological change of infected cells (CPE) is one of the culture confirmation methods used to estimate the virus species, but the morphological change itself may not be clearly observed. Therefore, to isolate the virus strain from the virus-infected cells and identify the virus, tests such as confirming the virus culture by the hemagglutination activity of the culture supernatant, and identifying the virus using genetic tests or antiviral antibodies are performed, and these tests are very laborious when handling a large number of specimens.

[0004] On the other hand, the present inventors have developed "BTP3-Neu5Ac" and "mC9-yne-BTP-Neu5Ac (BTP9-Neu5Ac)" shown in the following chemical formulas as detection reagents capable of highly sensitive fluorescent detection of viruses having sialidase activity, such as influenza virus, mumps virus, and human parainfluenza virus (see Non-Patent Document 1 and Patent Document 1). These detection reagents enable easy fluorescent imaging of virus-infected cells expressing sialidase.

[0005] [ka] [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Patent No. 6493964 [Non-patent literature]

[0007] [Non-Patent Document 1] Tadanori Takahashi, Yuki Kurebayashi, Tadamune Otsubo, Kiyoshi Ikeda, Akira Minami and Takashi Suzuki, "Fluorescence imaging of virus-infected cells using sialidase", Analytical Chemistry, 2016, Vol. 65, No. 12, pp. 689-701 Summary of the Invention [Problem to be solved by the invention]

[0008] As described above, there is a demand for diagnostic reagents that can be easily used in clinical practice to diagnose infection with influenza virus, mumps virus, and human parainfluenza virus, as well as a demand for technologies that can easily identify virus species from clinical specimens and easily isolate virus strains in health testing institutions and other such organizations.

[0009] On the other hand, the virus detection reagents "BTP3-Neu5Ac" and "mC9-yne-BTP-NeuAc (BTP9-Neu5Ac)" proposed in Non-Patent Document 1 and Patent Document 1 can detect sialidase-expressing viruses such as influenza virus, mumps virus, and human parainfluenza virus with high sensitivity, but have the problem that they cannot distinguish and determine each virus type.

[0010] Therefore, the present invention has been made in consideration of the above-mentioned points, and an object of the present invention is to provide a detection reagent capable of distinguishing and detecting virus species expressing sialidase. [Means for solving the problem]

[0011] The present inventors have focused on the sialic acid (Neu5Ac) structure of the sialidase substrate structure and discovered a novel sialic acid derivative compound that can distinguish and specifically detect the differences between sialidases of influenza virus, mumps virus, human parainfluenza virus, etc. Based on this finding, the present invention has been completed.

[0012] The present invention, which solves the above-mentioned problems, is a compound represented by the following formula (I), formula (II) or formula (III), or a salt thereof, or a solvate thereof, wherein in formula (II), R 1 represents a linear alkyl group having 3 to 9 carbon atoms or an isopropyl group.

[0013] [ka]

[0014] The compounds represented by formula (I), formula (II) or formula (III) are sialidase substrate compounds that react specifically with the sialidases of viruses expressing sialidase. Therefore, the viruses having sialidase activity can be detected by distinguishing them. More specifically, the influenza virus, mumps virus and human parainfluenza virus can be detected by distinguishing them by fluorescence, and the presence or absence of influenza A virus, influenza A virus with NA subtype N1, influenza A or B virus or mumps virus can be determined. This allows the compounds to be used in clinical diagnostics, for distinguishing virus species from clinical specimens, for isolating and culturing viruses and isolating virus strains.

[0015] In order to solve the above problems, the detection reagent of the present invention is a detection reagent for a virus having sialidase activity or a viral sialidase, and contains a compound represented by the following formula (I), formula (II), or formula (III), or a salt thereof, or a solvate thereof, wherein in formula (II), R 1represents a linear alkyl group having 3 to 9 carbon atoms or an isopropyl group.

[0016] [ka]

[0017] The above-mentioned compounds are sialidase substrate compounds that react specifically with the sialidases of viruses expressing sialidases. Therefore, it is possible to detect the virus species having sialidase activity and its sialidases in a differentiated manner. More specifically, it is possible to detect influenza A virus, influenza A virus with NA subtype N1, influenza A or B virus, or mumps virus and the sialidases of these viruses in a differentiated manner. In addition, these compounds can be used to perform histochemical fluorescence imaging of the site of sialidase activity in virus-infected cells. In addition, it is possible to perform live imaging of virus-infected cells, which can facilitate the isolation and culture of viruses from virus-infected cells and the isolation of virus strains.

[0018] In addition, the detection reagent of the present invention is a detection target virus for influenza virus, and contains a compound represented by the above-mentioned formula (I), formula (II) or formula (III), or a salt thereof, or a solvate thereof, and R in this formula (II) 1is also preferably an isopropyl group. The compound according to formula (I) is a sialidase substrate compound that distinguishes between the sialidase of influenza A virus and the sialidase of other virus species and specifically reacts with the sialidase of influenza A virus. Therefore, influenza A virus and its sialidase can be detected separately from other virus species. In addition, the compound according to formula (II) is a sialidase substrate compound that distinguishes between the sialidase of influenza A virus whose NA subtype is N1 and the sialidase of influenza A virus whose NA subtype is N2 and specifically reacts with the sialidase of influenza A virus whose NA subtype is N1. Therefore, influenza A virus whose NA subtype is N1 and its sialidase can be detected separately from influenza A virus whose NA subtype is N2 and its sialidase. The compound of formula (III) is a sialidase substrate compound that distinguishes between influenza A or B virus sialidase and sialidase of other virus species and specifically reacts with influenza A or B virus sialidase, and therefore can detect influenza A and B viruses and their sialidases in distinction from other virus species.

[0019] In addition, the detection reagent of the present invention is also preferably used when the virus to be detected is influenza A virus, and contains the compound represented by the above formula (I) or a salt thereof, or a solvate thereof. The compound according to formula (I) is a sialidase substrate compound that distinguishes between the sialidase of influenza A virus and the sialidase of other virus species and specifically reacts with the sialidase of influenza A virus. Therefore, influenza A virus and its sialidase can be detected in distinction from other virus species.

[0020] In addition, the detection reagent of the present invention is a detection target virus that is an influenza A virus with an NA subtype of N1, and contains a compound represented by formula (II) or a salt thereof, or a solvate thereof, and R 1is also preferably an isopropyl group. The compound according to formula (II) is a sialidase substrate compound that distinguishes between the sialidase of influenza A virus having an NA subtype of N1 and the sialidase of influenza A virus having an NA subtype of N2, and reacts with the sialidase of influenza A virus having an NA subtype of N1. Therefore, influenza A virus having an NA subtype of N1 and its sialidase can be detected in distinction from influenza A virus having an NA subtype of N2 and its sialidase.

[0021] In addition, the detection reagent of the present invention is also preferably used when the detection target virus is influenza A virus or influenza B virus, and contains a compound represented by formula (III) or a salt thereof, or a solvate thereof. The compound according to formula (III) is a sialidase substrate compound that distinguishes between the sialidase of influenza A or B virus and the sialidase of other virus species and specifically reacts with the sialidase of influenza A or B. Therefore, influenza A and B viruses and their sialidases can be detected in distinction from other virus species.

[0022] The detection method of the present invention is a method for detecting influenza virus, which comprises a compound represented by the above-mentioned formula (I), formula (II) or formula (III) or a salt thereof, or a solvate thereof, and R 1The method includes a step of adding a detection reagent having an isopropyl group to a specimen, and determining the presence or absence of influenza virus based on the fluorescent substance generated by this step. The compound according to formula (I) distinguishes between the sialidase of influenza A virus and that of other virus species, and reacts specifically with the sialidase of influenza A virus to generate the fluorescent substance BTP3 [(2-benzothiazol-2-yl)-4-bromophenol]. Therefore, influenza A virus can be detected in distinction from other virus species. The compound according to formula (II) distinguishes between the sialidase of influenza A virus with an NA subtype of N1 and that of influenza A virus with an NA subtype of N2, and reacts with the sialidase of influenza A virus with an NA subtype of N1 to generate the fluorescent substance BTP3. Therefore, influenza A virus with an NA subtype of N1 can be detected in distinction from influenza A virus with an NA subtype of N2. The compound of formula (III) can distinguish between influenza A or B virus sialidase and other virus species sialidase, and specifically reacts with influenza A or B virus sialidase to produce BTP3, which is a fluorescent substance, and can thus detect influenza A and B viruses in distinction from other virus species.

[0023] The detection method of the present invention is a method for detecting influenza virus, which comprises a compound represented by the above-mentioned formula (I), formula (II) or formula (III) or a salt thereof, or a solvate thereof, and R 1uses a detection reagent having an isopropyl group to perform fluorescent imaging of influenza virus-infected cells. The compound according to formula (I) reacts specifically with sialidase of influenza A virus to produce a fluorescent substance BTP3, and the site of influenza A virus in infected cells is histochemically fluorescently imaged by this BTP3. The compound according to formula (II) reacts specifically with sialidase of influenza A virus having an NA subtype of N1 to produce a fluorescent substance BTP3, and the site of influenza A virus in infected cells is histochemically fluorescently imaged by this BTP3. The compound according to formula (III) reacts specifically with sialidase of influenza A or B virus to produce a fluorescent substance BTP3, and the site of influenza A or B virus in infected cells is histochemically fluorescently imaged by this BTP3.

[0024] In addition, the detection reagent of the present invention is a detection target virus for mumps virus, and contains the compound represented by the above formula (II) or a salt thereof, or a solvate thereof, and R 1 is also preferably a linear alkyl group having 3 to 9 carbon atoms. These compounds are sialidase substrate compounds that distinguish the difference between mumps virus sialidase and sialidases of other virus species and specifically react with mumps virus sialidase. Therefore, mumps virus and its sialidase can be detected in distinction from other virus species.

[0025] In addition, the detection reagent of the present invention is a detection target virus for mumps virus, and contains the compound represented by the above formula (II) or a salt thereof, or a solvate thereof, and R 1is also preferably a heptyl group. This compound is a sialidase substrate compound that distinguishes between mumps virus sialidase and sialidases of other virus species, specifically reacts with mumps virus sialidase, and has high reactivity. Therefore, mumps virus and its sialidase can be detected in distinction from other virus species.

[0026] The detection method of the present invention is a method for detecting mumps virus, which is represented by the above formula (II), and R 1 The present invention relates to a method for determining the presence or absence of mumps virus by adding a detection reagent containing a compound having 3 to 9 carbon atoms, a salt thereof, or a solvate thereof to a specimen, and determining the presence or absence of mumps virus based on the fluorescent substance generated by this step. These compounds distinguish the difference between the sialidase of mumps virus and the sialidase of other virus species, and react specifically with the sialidase of mumps virus to generate the fluorescent substance BTP3 [(2-benzothiazol-2-yl)-4-bromophenol]. Therefore, the mumps virus can be detected in distinction from other virus species.

[0027] The detection method of the present invention is a method for detecting mumps virus, which is represented by the above formula (II), and R 1 The present invention performs fluorescent imaging of mumps virus-infected cells using a detection reagent containing a compound that is a linear alkyl group having 3 to 9 carbon atoms or a salt thereof, or a solvate thereof. These compounds react specifically with mumps virus sialidase to produce BTP3, a fluorescent substance, and the site of mumps virus presence in the infected cells is histochemically fluorescently imaged by this BTP3. Effect of the Invention

[0028] According to the present invention, it is possible to provide a virus detection reagent and a virus detection method having the following excellent effects. (1) By adding the compound according to the present invention to a sample, it is possible to easily detect a virus species having sialidase activity and its sialidase in a distinguishable manner. (2) The compound itself is relatively easy to synthesize. (3) The location of the virus in virus-infected cells can be histochemically imaged using fluorescent imaging. (4) Live imaging of virus-infected cells is possible, facilitating the isolation and culture of viruses from virus-infected cells and the isolation of virus strains. [Brief description of the drawings]

[0029] [Figure 1] 1 is a graph showing the results of screening for compounds that detect influenza A virus sialidase in Example 1. [Diagram 2] 1 is a graph showing the reactivity of compound b (22-001a) and compound a (positive control, BTP3-Neu5Ac) to sialidases of other virus species in Example 2. [Diagram 3] 1 is a graph showing the reactivity of compound b (22-001a) and compound a (positive control, BTP3-Neu5Ac) against sialidases of influenza A viruses or other virus species having different NA subtypes in Example 3. [Figure 4] 1 is a photograph showing fluorescent imaging images of virus-infected cells using compound b (22-001a) and compound a (positive control, BTP3-Neu5Ac) in Example 4. [Diagram 5] 1 is a photograph showing fluorescent imaging images of cells infected with influenza A and B virus strains using compound b (22-001a) in Example 5. [Figure 6] 1 is a photograph showing a fluorescent imaging image of influenza A virus foci by compound b (22-001a) in Example 6. [Figure 7]1 is a photograph showing fluorescent imaging images of viral foci using compound b (22-001a) and compound a (positive control, BTP3-Neu5Ac) in Example 7. [Figure 8] FIG. 1 is a graph showing the reactivity of compound k (23-139b), compound l (23-136b4), compound a (positive control; BTP3-Neu5Ac), and compound b (22-001a) to sialidase of influenza A virus (A / PR / 8 / 1934 H1N1 strain) in Example 8. [Figure 9] 1 is a graph showing the reactivity of compound k (23-139b), compound l (23-136b4), compound a (BTP3-Neu5Ac), and compound b (22-001a) to sialidase of influenza B virus (B / Lee / 1940 strain) in Example 8. [Figure 10] FIG. 1 is a graph showing the reactivity of compound k (23-139b), compound l (23-136b4), and compound a (BTP3-Neu5Ac) to sialidase of influenza A virus (A / Shizuoka / 838 / 2009 H1N1 strain, A / Shizuoka / 738 / 2008 H1N1 strain, and A / Memphis / 1 / 1971 H3N2 strain) in Example 8. [Figure 11] 1 is a graph showing the reactivity of compound k (23-139b), compound l (23-136b4), and compound a (BTP3-Neu5Ac) to sialidases of other virus species in Example 8. [Figure 12] 1 is a photograph showing fluorescent imaging images of virus-infected cells using compound k (23-139b) and compound a (positive control, BTP3-Neu5Ac) in Example 9. [Figure 13] FIG. 13 is a graph showing the reactivity of compound c (22-002b_i), compound e (22-002b_t), compound f (22-005b_c), compound g (22-005b_b), and compound a (positive control, BTP3-Neu5Ac) in Example 10 against sialidases of influenza A virus and influenza B virus having different NA subtypes. [Figure 14] 1 shows photographs depicting fluorescent imaging images of virus-infected cells using compound c (22-002b_i) and compound a (positive control, BTP3-Neu5Ac) in Example 11. [Figure 15] 1 is a graph showing the results of screening for compounds that detect mumps virus sialidase in Example 12. [Figure 16] FIG. 13 is a graph showing the reactivity to sialidases of other virus species in Example 13, showing the test results of (a) compound f (22-005b_c), (b) compound d (22-002b_4), (c) compound c (22-002b_i), (d) compound h (22-005b_8), (e) compound i (22-005b_6), and (f) compound j (22-005b_7). [Figure 17] 1 is a photograph showing fluorescent imaging images of virus-infected cells using compound h (22-005b_8) and compound a (positive control, BTP3-Neu5Ac) in Example 14. [Figure 18] 1 is a graph showing (a) the reactivity of each compound in Example 15 to sialidase of the mumps virus 13V165E2 strain, and (b) the reactivity of each compound to sialidase of the influenza A virus A / Shizuoka / 738 / 2008 H1N1 strain. [Figure 19] 1 is a graph showing (a) the reactivity of each compound in Example 15 to sialidase from influenza B virus B / Lee / 1940 strain, and (b) the reactivity of each compound to sialidase from human parainfluenza virus serotype 1 C35 strain. [Figure 20] 1 is a graph showing the reactivity of each compound in Example 15 to sialidase from human parainfluenza virus serotype 3 C243 strain. [Figure 21] 1 shows photographs depicting (a) fluorescent imaging images of mumps virus-infected cells and (b) fluorescent imaging images of influenza A virus-infected cells, using each compound in Example 16. [Figure 22]13 is a photograph showing (a) a fluorescent imaging image of influenza B virus-infected cells and (b) a fluorescent imaging image of human parainfluenza virus serotype 1-infected cells by each compound in Example 16. [Diagram 23] 1 shows photographs depicting fluorescent imaging images of cells infected with human parainfluenza virus serotype 3 using each compound in Example 16. [Figure 24] 1 shows photographs depicting fluorescent imaging images of mumps virus-infected cells using each compound in Example 17. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] The novel compound, the virus detection reagent, and the virus detection method according to the present invention will be described in detail below.

[0031] The virus detection reagent according to the present invention contains a sialic acid derivative represented by the following formula (I), formula (II) or formula (III). The compound according to the sialic acid derivative according to the present invention may be a salt, and is preferably a pharmacologically acceptable salt. The pharmacologically acceptable salt of this compound is not particularly limited as long as it is a salt formed with an acid or a base. In addition, this compound or its salt may be a solvate, and examples of the solvate include, but are not limited to, a hydrate and an organic solvent solvate such as ethanol.

[0032] [ka]

[0033] The names of the compounds of formula (I) which represent the above-mentioned compounds are as follows: Formula (I): 5-acetamido-2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)(hydroxy)methyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid.

[0034] In addition, in the formula (II) representing the above-mentioned compound, R 1 The atom or molecule represented by the formula (II) may be a linear alkyl group having 3 to 9 carbon atoms or an isopropyl group. The compound represented by the formula (II) above is specifically the compounds (1) to (8) represented by the following formulas. The names of the compounds of each formula are as follows: Formula (1): 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-butylamido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid. Formula (2): 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-pentanamido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid. Formula (3): 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-hexanamido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid. Formula (4): 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-heptanamido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid. Formula (5): 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-octanamido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid. Formula (6): 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-nonanamido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid. Formula (7): 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-decanamido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid. Formula (8): 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-isobutyramido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid.

[0035] [ka]

[0036] [ka]

[0037] [ka]

[0038] [ka]

[0039] [ka]

[0040] [ka]

[0041] [ka]

[0042] [ka]

[0043] The names of the compounds of formula (III) which represent the above-mentioned compounds are as follows: Formula (III): 5-acetamido-2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-6-((2-methyl-2-ethyl-1,3-dioxolan-4-yl)(hydroxy)methyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid.

[0044] Among the compounds represented by each formula, the compound contained in the detection reagent for influenza A virus or its sialidase is 5-acetamido-2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-6-((2,2-dimethyl-1,3-dioxolan-4-yl)(hydroxy)methyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid shown in formula (I).

[0045] The compound shown in formula (I) can be synthesized, for example, by the synthetic route shown in the following formula. As an example, sodium methoxide is added to a methanol solution of a known compound X (see PLOS ONE, 2014, Vol. 9, No. 1, e81941) to react with it to obtain a tetrahydroxy compound, and the obtained tetrahydroxy compound is suspended in acetone, and acetone dimethyl acetal (DMP) and pyridinium paratoluenesulfonate (PPTS) are added and reacted to obtain compound Y shown in the following formula. The compound shown in formula (I) can be obtained by adding methanol and an aqueous sodium hydroxide solution to compound Y and reacting it.

[0046] [ka]

[0047] Among the compounds represented by each formula, the compound contained in the detection reagent for influenza A and B viruses and their sialidase is 5-acetamido-2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-6-((2-methyl-2-ethyl-1,3-dioxolan-4-yl)(hydroxy)methyl)-4-hydroxytetrahydro-2H-pyran-2-carboxylic acid shown in formula (III).

[0048] The compound represented by formula (III) can be synthesized, for example, by the synthetic route represented by the following formula. As an example, sodium methoxide is added to a methanol solution of a known compound X (see PLOS ONE, 2014, Vol. 9, No. 1, e81941) to react with the compound to obtain a tetrahydroxy compound, and the resulting tetrahydroxy compound is dissolved in acetonitrile (or DMF), and a corresponding ketone-ketone dimethyl acetal solution containing camphorsulfonic acid (CSA) is added to the resulting methyl ester of the acetal compound. The compound represented by formula (III) can be obtained by adding methanol and an aqueous sodium hydroxide solution to the resulting methyl ester. The corresponding ketone-ketone dimethyl acetal solution containing camphorsulfonic acid (CSA) can be prepared as a ketone-ketone dimethyl acetal-CSA solution by adding camphorsulfonic acid (CSA) to a mixed solution of the corresponding ketone and trimethyl orthoformate represented by the following formula, for example.

[0049] [ka]

[0050] Furthermore, among the compounds represented by each formula, the compounds contained in the reagent for detecting mumps virus or its sialidase are preferably the compounds represented by formulas (1) to (7), and from the viewpoints of excellent specific detectability and excellent fluorescence intensity during detection, the compounds represented by formulas (2) to (6) are more preferable, and 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-octanamido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid represented by formula (5) is particularly preferable.

[0051] Among the compounds represented by each formula, the compound contained in the detection reagent for influenza A virus whose NA subtype is N1 or its sialidase is 2-(2-(benzothiazol-2-yl)-4-bromophenoxy)-4-hydroxy-5-isobutyramido-6-(1,2,3-trihydroxypropyl)tetrahydro-2H-pyran-2-carboxylic acid shown in formula (8).

[0052] The compounds shown in formulas (1) to (8) can be synthesized, for example, by the synthetic route shown in the following formula. As an example, the compound according to formula (1) is obtained by adding Boc2O and 4-dimethylaminopyridine (DMAP) to a tetrahydrofuran (THF) solution of a known compound X (see PLOS ONE, 2014, Vol. 9, No. 1, e81941) and reacting at 60°C, and then adding N,N-dimethylethylenediamine to the reaction solution and reacting it to obtain compound Z. Trifluoroacetic acid (TFA) is added to compound Z to obtain a deprotected form as a TFA salt, and then the compound is dissolved in ethyl acetate, water and sodium bicarbonate are added, and butyric anhydride is added as a reaction reagent to react, to obtain compound E (1). Methanol and sodium methoxide are added to the obtained compound E (1) to react, and then an aqueous sodium hydroxide solution is added to react, to obtain compound (1). By appropriately selecting a reaction reagent compound instead of butyric anhydride as the reaction reagent used here, the compounds shown in formulas (2) to (8) can be obtained in the same manner as the compound shown in formula (1).

[0053] [ka]

[0054] The detection reagent of the present invention is a detection reagent for detecting a virus having sialidase activity or a sialidase of a virus. Viruses having sialidase activity include influenza virus, human parainfluenza virus, mumps virus, Newcastle disease virus, and Sendai virus, all of which are single-stranded negative-strand RNA viruses, and influenza virus belongs to the family Orthomyxoviridae, while the other viruses belong to the family Paramyxoviridae. The detection reagent of the present invention can distinguish and detect influenza A virus, influenza A virus with NA subtype N1, influenza A or B virus, or mumps virus, and their sialidases. In addition, the detection reagent of the present invention can perform histochemical fluorescence imaging of the site of virus presence in virus-infected cells, and can perform live imaging of virus-infected cells. Therefore, the detection reagent of the present invention can be used not only as a simple fluorescence measurement reagent, but also as a fluorescence imaging agent.

[0055] In addition, the detection reagent of the present invention may contain other components other than those described above, as long as the effects of the present invention are not impaired. For example, solvents, pH adjusters, pH buffers, inorganic salts, etc. are included. In addition, the detection reagent of the present invention can be used in all situations, such as research reagents, clinical diagnostic drugs, and clinical analytical drugs.

[0056] A method for detecting influenza A virus or sialidase of influenza A virus using a detection reagent containing a compound represented by formula (I) according to the present invention will be described. First, a detection reagent containing a compound represented by formula (I) is used as the detection reagent. When this is added to a specimen, if influenza A virus or sialidase of influenza A virus is present in the specimen, the compound represented by formula (I) reacts specifically with the sialidase of influenza A virus to generate BTP3, which is a fluorescent substance. Here, the compound represented by formula (I) does not react with viruses other than influenza A virus or sialidases other than influenza A virus, and does not generate a fluorescent substance. Therefore, when the fluorescence due to BTP3, which is a fluorescent substance, is detected by adding a detection reagent containing a compound represented by formula (I) to a specimen, it is possible to determine that influenza A virus or its sialidase is present. The reaction concentration of the compound represented by formula (I) varies depending on the specimen and the mode of use, but is preferably 5 μM to 100 mM, more preferably 10 μM to 10 mM. The reaction time depends on the concentration of the compound and the state of the specimen to be added, but for example, when the compound is added to a suspension or culture solution, it is preferably from several minutes to about 1 hour, more preferably from about 5 minutes to 30 minutes, and when the compound is added to a specimen such as an agar medium, it is preferably from several hours to about 1 day, more preferably from about 3 hours to 12 hours.

[0057] In addition, a method for detecting influenza A virus-infected cells by fluorescence imaging according to the present invention will be described. When a detection reagent containing a compound represented by formula (I) is added to a specimen, if influenza A virus-infected cells are present in the specimen, the sialidase expressed by the influenza A virus reacts specifically with the compound represented by formula (I) to generate BTP3, a fluorescent substance. BTP3 is a fluorescent substance insoluble in water and has local staining properties. Here, the compound represented by formula (I) does not react with sialidase expressed by viruses other than influenza A virus, and does not generate a fluorescent substance. Therefore, if influenza A virus-infected cells are present in the specimen, the site where the infected cells are present is histochemically fluorescently imaged. The reaction concentration of the compound represented by formula (I) varies depending on the specimen and the mode of use, but is preferably 5 μM to 100 mM, more preferably 10 μM to 10 mM. The reaction time depends on the concentration of the compound and the state of the specimen to be added, but as an example, when added to a culture medium, it is preferably several minutes to about 1 hour, more preferably about 5 minutes to 30 minutes. When added to a specimen such as an agar medium, it is preferably several hours to about 1 day, more preferably about 3 hours to 12 hours. Furthermore, since this fluorescence imaging can be performed by live imaging, it is possible to easily isolate influenza A virus strains even from specimens containing a mixture of various virus species by using this fluorescence imaging.

[0058] Next, a method for detecting influenza A and B viruses and their sialidases using a detection reagent containing a compound represented by formula (III) according to the present invention will be described. First, a detection reagent containing a compound represented by formula (III) is used as the detection reagent. When this is added to a specimen, if influenza A virus or influenza B virus, or sialidase of these influenza viruses is present in the specimen, the compound represented by formula (III) reacts specifically with the sialidase of the influenza A virus or the sialidase of the influenza B virus to generate BTP3, which is a fluorescent substance. Here, the compound represented by formula (III) hardly reacts with viruses other than influenza A and B viruses or sialidases other than influenza A and B viruses. Therefore, when the fluorescence due to the fluorescent substance BTP3 is detected by adding a detection reagent containing a compound represented by formula (III) to a specimen, it can be determined that influenza A virus or influenza B virus or their sialidases are present. The reaction concentration of the compound represented by formula (III) varies depending on the specimen and the mode of use, but is preferably 5 μM to 100 mM, more preferably 10 μM to 10 mM. The reaction time depends on the concentration of the compound and the state of the specimen to be added, but as an example, when added to a suspension or culture solution, it is preferably several minutes to about 1 hour, more preferably about 5 minutes to 30 minutes. When added to a specimen such as an agar medium, it is preferably several hours to about 1 day, more preferably about 3 hours to 12 hours.

[0059] In addition, a method for detecting cells infected with influenza virus type A or type B by fluorescent imaging according to the present invention will be described. When a detection reagent containing a compound represented by formula (III) is added to a specimen, if a cell infected with influenza virus type A or type B is present in the specimen, the sialidase expressed by influenza virus type A or type B reacts specifically with the compound represented by formula (III) to generate fluorescent substance BTP3. BTP3 is a fluorescent substance insoluble in water and has local staining properties. Here, the compound represented by formula (III) hardly reacts with sialidase expressed by viruses other than influenza virus type A or type B. Therefore, if a cell infected with influenza virus type A or type B is present in the specimen, the site where the infected cell exists is histochemically fluorescently imaged. The reaction concentration of the compound represented by formula (III) varies depending on the specimen and the mode of use, but is preferably 5 μM to 100 mM, more preferably 10 μM to 10 mM. The reaction time depends on the concentration of the compound and the state of the specimen to be added, but for example, when added to a culture medium, it is preferably several minutes to about 1 hour, more preferably about 5 minutes to 30 minutes, and when added to a specimen such as an agar medium, it is preferably several hours to about 1 day, more preferably about 3 hours to 12 hours.

[0060] Next, a method for detecting influenza A virus having an NA subtype of N1 or its sialidase using a detection reagent containing a compound represented by formula (8) according to the present invention will be described. First, a detection reagent containing a compound represented by formula (8) is used as the detection reagent. When this is added to a specimen, if influenza A virus having an NA subtype of N1 or its sialidase is present in the specimen, the compound represented by formula (8) reacts with the sialidase of the influenza A virus having an NA subtype of N1 to generate a fluorescent substance BTP3. Here, the compound represented by formula (8) does not react with the sialidase of influenza A virus having an NA subtype of N2, and no fluorescent substance is generated. Therefore, when the fluorescence due to the fluorescent substance BTP3 is detected by adding a detection reagent containing a compound represented by formula (8) to a specimen, it can be determined that influenza A virus having an NA subtype of N1 or its sialidase is present. In addition, since the compound shown in formula (8) also reacts slightly with mumps virus sialidase and human parainfluenza virus sialidase, it is preferable to perform screening in advance using a compound shown in formula (I) or formula (III) capable of specifically detecting influenza A virus sialidase, and then perform detection using the compound shown in formula (8) to identify the subtype. The reaction concentration of the compound shown in formula (8) varies depending on the specimen and the mode of use, but is preferably 5 μM to 100 mM, more preferably 10 μM to 10 mM. In addition, the reaction time depends on the concentration of the compound and the state of the specimen to be added, but as an example, when added to a suspension or culture solution, it is preferably several minutes to about 1 hour, more preferably about 5 minutes to 30 minutes. In addition, when added to a specimen such as an agar medium, it is preferably several hours to about 1 day, more preferably about 3 hours to 12 hours.

[0061] In addition, a method for detecting a cell infected with influenza A virus having an NA subtype of N1 by fluorescence imaging according to the present invention will be described. When a detection reagent containing a compound represented by formula (8) is added to a specimen, if a cell infected with influenza A virus having an NA subtype of N1 is present in the specimen, the sialidase expressed by the influenza A virus having an NA subtype of N1 reacts with the compound represented by formula (8) to generate BTP3, a fluorescent substance. BTP3 is a fluorescent substance insoluble in water and has local staining properties. Here, the compound represented by formula (8) does not react with sialidase expressed by influenza A virus having an NA subtype of N2, and does not generate a fluorescent substance. Therefore, if a cell infected with influenza A virus having an NA subtype of N1 is present in the specimen, the site where the infected cell exists is histochemically fluorescently imaged. The reaction concentration of the compound represented by formula (8) varies depending on the specimen and the mode of use, but is preferably 5 μM to 100 mM, more preferably 10 μM to 10 mM. The reaction time depends on the concentration of the compound and the state of the specimen to be added, but for example, when added to a culture medium, it is preferably several minutes to about 1 hour, more preferably about 5 minutes to 30 minutes, and when added to a specimen such as an agar medium, it is preferably several hours to about 1 day, more preferably about 3 hours to 12 hours.

[0062] Next, the method for detecting mumps virus or its sialidase according to the present invention will be described. First, a detection reagent containing the compounds shown in the above formulas (1) to (7) is used as the detection reagent. When this is added to a specimen, if mumps virus or its sialidase is present in the specimen, the compounds shown in the formulas (1) to (7) react specifically with mumps virus sialidase to generate fluorescent substance BTP3. Here, the compounds shown in the formulas (1) to (7) do not react with viruses other than mumps virus or sialidases other than mumps virus, and do not generate fluorescent substances. Therefore, when the fluorescence due to fluorescent substance BTP3 is detected by adding the detection reagent containing the compounds shown in the formulas (1) to (7) to a specimen, it is possible to determine the presence of mumps virus or its sialidase. The reaction concentration of the compounds shown in the formulas (1) to (7) varies depending on the specimen and the mode of use, but is preferably 5 μM to 100 mM, more preferably 10 μM to 10 mM. The reaction time depends on the concentration of the compound and the state of the specimen to be added, but for example, when the compound is added to a suspension or culture solution, it is preferably from several minutes to about 1 hour, more preferably from about 5 minutes to 30 minutes, and when the compound is added to a specimen such as an agar medium, it is preferably from several hours to about 1 day, more preferably from about 3 hours to 12 hours.

[0063] In addition, a method for detecting mumps virus-infected cells by fluorescence imaging according to the present invention will be described. When a detection reagent containing the compounds shown in formulae (1) to (7) is added to a specimen, if mumps virus-infected cells are present in the specimen, the sialidase expressed by the mumps virus reacts specifically with the compounds shown in formulae (1) to (7), generating BTP3, a fluorescent substance. BTP3 is a fluorescent substance insoluble in water and has local staining properties. Here, the compounds shown in formulae (1) to (7) do not react with sialidase expressed by viruses other than mumps virus, and do not generate fluorescent substances. Therefore, if mumps virus-infected cells are present in the specimen, the site where the infected cells are present is histochemically fluorescently imaged. The reaction concentration of the compounds shown in formulae (1) to (7) varies depending on the specimen and the mode of use, but is preferably 5 μM to 100 mM, more preferably 10 μM to 10 mM. The reaction time depends on the concentration of the compound and the state of the specimen to be added, but as an example, when added to a culture medium, it is preferably several minutes to about 1 hour, more preferably about 5 minutes to 30 minutes. When added to a specimen such as an agar medium, it is preferably several hours to about 1 day, more preferably about 3 hours to 12 hours. Furthermore, since this fluorescence imaging can be performed by live imaging, it is possible to easily isolate mumps virus strains even from specimens containing a mixture of various virus species by using this fluorescence imaging.

[0064] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to these examples in any way. EXAMPLES

[0065] [Example 1] 1. Screening of compounds that detect influenza A virus sialidase In this example, a derivative in which the sialic acid structure portion of BTP3-Neu5Ac, a known sialidase substrate, was modified was selected as the screening target compound. The screening target compounds are shown in Table 1 below. A search for a compound capable of detecting influenza A virus sialidase was performed by a test for measuring the sialidase activity of influenza A virus. Specifically, the search was performed by measuring the fluorescence intensity of BTP3 [(2-benzothiazol-2-yl)-4-bromophenol], a fluorescent substance generated by hydrolysis by influenza A virus sialidase when the influenza A virus sialidase was reacted with the screening target compound. In the test, BTP3-Neu5Ac (compound a) was used as a positive control. BTP3-Neu5Ac of compound a was manufactured by Tokyo Chemical Industry Co., Ltd. The compounds shown in b to h in Table 1 below were synthesized as follows. It was confirmed by high-resolution mass spectrometry (HRMS) that the compound obtained by synthesis (including intermediates) was the target product. High-resolution mass spectrometry was performed using an AccuTOF (JMS-T100LC) manufactured by JEOL Ltd., connected to an electrospray ion source (ES) and in positive mode.

[0066] [Table 1]

[0067] [Synthesis of compound b (22-001a)] Compound b was synthesized based on the following formula:

[0068] [ka]

[0069] A sodium methoxide solution (5M in MeOH, 4.0mL) was added to a methanol solution (150mL) of 14.93g (19.2mmol) of known compound X (see PLOS ONE, 2014, Vol. 9, No. 1, e81941) and stirred at room temperature for 2 hours. Sodium methoxide (1.5mL) was added twice every hour while checking the thin layer chromatography. After confirming the disappearance of the raw material, acetic acid (1.5mL) was added to stop the reaction. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (100% ethyl acetate) to obtain the tetrahydroxy compound (6.68g, 57% yield) as a white solid. HRMS (ESI-TOF) Calcd for C 25 H 27 79 BrN2NaO9S [M+Na] + : 633.05183; Found: 633.05172, Calcd for C 25 H 27 81 BrN2NaO9S [M+Na] + : 635.04979; Found: 635.05115.

[0070] The obtained tetrahydroxy compound (6.68g, 10.9mmol) was suspended in acetone (90mL), and acetone dimethyl acetal (DMP, 6.68mL, 5.0eq.) and pyridinium paratoluenesulfonate (PPTS, 549mg, 0.2eq.) were added in that order and stirred at room temperature for 3 hours. DMP (6.68mL) and PPTS (560mg) were added and further stirred. After confirming the disappearance of the raw materials by thin layer chromatography, a saturated aqueous solution of sodium bicarbonate (20mL) was added to stop the reaction. The organic layer was diluted with ethyl acetate, washed with water (three times) and saturated saline (one time) in that order, and dried over sodium sulfate. The desiccant was filtered off, concentrated under reduced pressure, and the residue obtained was purified by silica gel column chromatography (ethyl acetate:methanol = 7:1) to obtain compound Y as a white solid (5.30g, yield 75%). HRMS (ESI-TOF) Calcd for C 28 H 31 79BrN2NaO9S [M+Na] + : 673.08313; Found: 673.08363, Calcd for C 28 H 31 81 BrN2NaO9S [M+Na] + : 675.08109; Found: 675.08145.

[0071] Subsequently, methanol (1 mL) and an aqueous solution of sodium hydroxide (2.5 M, 150 μL) were added to compound Y (163 mg, 0.25 mmol) in that order and stirred at room temperature overnight. The reaction was stopped by adding acetic acid (15 μL) to the reaction solution, and the solution was purified by high performance liquid chromatography to obtain compound b (93.8 mg, 59% yield) as a white solid. HRMS (ESI-TOF) Calcd for C 27 H 29 79 BrN2NaO9S [M+Na] + : 659.06748; Found: 659.06992, Calcd for C 27 H 29 81 BrN2NaO9S [M+Na] + : 661.06544; Found: 661.06630.

[0072] [Synthesis of compounds c-h] Compounds c to h were synthesized based on the following formula: In the following formula, R in compounds Ec and c is an isopropyl group, R in compounds Ed and d is a propyl group, R in compounds Ee and e is a tert-butyl group, R in compounds Ef and f is a methoxy group, R in compounds Eg and g is a phenyl group, and R in compounds Eh and h is a heptyl group.

[0073] [ka]

[0074] [Synthesis of compound c (22-002b_i)] To a solution (150 mL) of 15.84 g (20.3 mmol) of known compound X (see PLOS ONE, 2014, Vol. 9, No. 1, e81941), Boc2O (6.87 g, 1.5 eq.), 4-dimethylaminopyridine (DMAP, 249 mg, 0.1 eq.) were added and stirred at 60°C overnight. After confirming the disappearance of the raw materials by thin layer chromatography, the mixture was allowed to cool. N,N-dimethylethylenediamine (4.5 mL, 2.0 eq.) was added to the reaction solution and stirred at room temperature overnight. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water (three times) and saturated saline (one time) in that order, and dried over sodium sulfate. The desiccant was filtered off, and the residue obtained by concentrating under reduced pressure was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain compound Z as a white foam (8.25 g, 49% yield). HRMS (ESI-TOF) Calcd for C 36 H 41 79 BrN2NaO 14 S [M+Na] + 859.13596; Found 859.13463, Calcd for C 36 H 41 81 BrN2NaO 14 S [M+Na] + 861.13391; Found 861.13193.

[0075] Subsequently, trifluoroacetic acid (10 mL) was added to compound Z (838 mg, 1 mmol) and stirred at room temperature for 30 minutes. The solvent was concentrated under reduced pressure to obtain the deprotected product as a TFA salt. The obtained unpurified deprotected product was dissolved in ethyl acetate (40 mL). Water (10 mL) and sodium bicarbonate (840 mg, 10 mmol) were added to a solution (10 mL) of the starting amine TFA salt in ethyl acetate, and isobutyric anhydride (63 μL, 1.5 eq.) was added and stirred for 14 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed successively with water (three times) and saturated saline (once), and dried over sodium sulfate. The drying agent was filtered off and the mixture was concentrated under reduced pressure to obtain compound Ec (208 mg). The obtained compound was used in the next reaction without purification.

[0076] Methanol (1 mL) and sodium methoxide solution (5M in MeOH, 0.5 mL) were added to the unpurified compound Ec (200 mg) in sequence and stirred for 20 minutes. Sodium hydroxide solution (5M, 0.2 mL) was then added and stirred overnight. After confirming the disappearance of the raw materials by thin layer chromatography, acetic acid (200 μL) was added to stop the reaction, and the compound c (14.2 mg) was obtained as a white powder by HPLC purification. HRMS (ESI-TOF) Calcd for C 26 H 30 79 BrNO9S [M+H] + : 625.08554; Found: 625.08823, Calcd for C 26 H 30 81 BrNO9S [M+H] + : 627.08349; Found: 627.08348, Calcd for C 26 H 29 79 BrN2NaO9S [M+Na] + : 647.06748; Found: 647.06603, Calcd for C 26 H 29 81 BrN2NaO9S [M+Na] + : 649.06544; Found: 649.06682.

[0077] [Synthesis of compound d (22-002b_4)] Compound d was synthesized as follows. Compound Ed (233 mg) was obtained by carrying out the same materials and reactions as in the synthesis method of compound c, except that butyric anhydride (61 μL) was used instead of isobutyric anhydride used in the synthesis route of compound Ec in the synthesis method of compound c described above. The obtained compound was used in the next reaction without purification. Unpurified compound Ed (200 mg) was added with methanol (1 mL) and sodium methoxide solution (5 M in MeOH, 0.5 mL) in that order and stirred for 20 minutes. Successively, an aqueous sodium hydroxide solution (5 M, 0.2 mL) was added and stirred overnight. After confirming the disappearance of the raw material by thin layer chromatography, acetic acid (200 μL) was added to stop the reaction, and the compound d (20.7 mg) was obtained as a white powder by purifying it by high performance liquid chromatography. HRMS (ESI-TOF) Calcd for C 26 H 30 79 BrNO9S [M+H] + : 625.08554; Found: 625.08433, Calcd for C 26 H 30 81 BrNO9S [M+H] + : 627.08349; Found: 627.08151, Calcd for C 26 H 29 79 BrN2NaO9S [M+Na] + : 647.06748; Found: 647.06345, Calcd for C 26 H 29 81 BrN2NaO9S [M+Na] + : 649.06544; Found: 649.06531.

[0078] [Synthesis of compound e (22-002b_t)] Compound e was synthesized as follows. Compound Ee (194 mg) was obtained by carrying out the same materials and reactions as in the synthesis method of compound c, except that pivaloyl chloride (46 μL) was used instead of isobutyric anhydride used in the synthesis route of compound Ec in the synthesis method of compound c described above. The obtained compound was used in the next reaction without purification. Unpurified compound Ee (194 mg) was added with methanol (1 mL) and sodium methoxide solution (5 M in MeOH, 0.5 mL) in that order and stirred for 20 minutes. Successively, an aqueous sodium hydroxide solution (5 M, 0.2 mL) was added and stirred overnight. After confirming the disappearance of the raw material by thin layer chromatography, acetic acid (200 μL) was added to stop the reaction, and the compound e (25.6 mg) was obtained as a white powder by purifying it by high performance liquid chromatography. HRMS (ESI-TOF) Calcd for C 27 H 32 79 BrNO9S [M+H] + : 639.10119; Found: 639.09942, Calcd for C 27 H 32 81 BrNO9S [M+H] + : 641.09914; Found: 641.09765.

[0079] [Synthesis of compound f (22-005b_c)] Compound f was synthesized as follows. Compound Ef (197 mg) was obtained by carrying out the same materials and reactions as in the synthesis method of compound c, except that methyl chloroformate (100 μL) was used instead of isobutyric anhydride used in the synthesis route of compound Ec in the synthesis method of compound c described above. The obtained compound was used in the next reaction without purification. Unpurified compound Ef (197 mg) was added with methanol (1 mL) and sodium methoxide solution (5 M in MeOH, 0.5 mL) in that order and stirred for 20 minutes. Successively, an aqueous sodium hydroxide solution (5 M, 0.2 mL) was added and stirred overnight. After confirming the disappearance of the raw material by thin layer chromatography, acetic acid (200 μL) was added to stop the reaction, and the compound f was obtained as a white powder by purifying it by high performance liquid chromatography. HRMS (ESI-TOF) Calcd for C 24 H 26 79 BrNO 10 S [M+H] + : 613.04915; Found: 613.05138, Calcd for C 24 H 26 81 BrNO 10 S [M+H] + : 615.04711; Found: 615.04780, Calcd for C 24 H 25 79 BrN2NaO 10 S [M+Na] + : 635.03110; Found: 635.03255, Calcd for C 24 H 25 81 BrN2NaO 10 S [M+Na] + : 637.02905; Found: 637.02923.

[0080] [Synthesis of compound g (22-005b_b)] Compound g was synthesized as follows. Compound Eg (235 mg) was obtained by carrying out the same materials and reactions as in the synthesis method of compound c, except that benzoyl chloride (100 μL) was used instead of the isobutyric anhydride used in the synthesis route of compound Ec in the synthesis method of compound c described above. The obtained compound was used in the next reaction without purification. Unpurified compound Eg (200 mg) was added with methanol (1 mL) and sodium methoxide solution (5 M in MeOH, 0.5 mL) in that order and stirred for 20 minutes. Successively, an aqueous sodium hydroxide solution (5 M, 0.2 mL) was added and stirred overnight. After confirming the disappearance of the raw material by thin layer chromatography, acetic acid (200 μL) was added to stop the reaction, and the compound g was obtained as a white powder by purifying it by high performance liquid chromatography. HRMS (ESI-TOF) Calcd for C 29 H 27 79 BrN2NaO9S [M+Na]+ : 681.05183; Found: 681.05292, Calcd for C 29 H 27 81 BrN2NaO9S [M+Na] + : 683.04979; Found: 683.04819, Calcd for C 29 H 26 79 BrN2Na2O9S [M-H+2Na] + : 703.03378; Found: 703.03642, Calcd for C 29 H 26 81 BrN2Na2O9S [M-H+2Na] + : 705.03173; Found: 705.03320.

[0081] [Synthesis of compound h (22-005b_8)] Compound h was synthesized as follows. Compound Eh (258 mg) was obtained by carrying out the same materials and reactions as in the synthesis method of compound c, except that octanoyl chloride (100 μL) was used instead of isobutyric anhydride used in the synthesis route of compound Ec in the synthesis method of compound c described above. The obtained compound was used in the next reaction without purification. Unpurified compound Eh (200 mg) was added with methanol (1 mL) and sodium methoxide solution (5 M in MeOH, 0.5 mL) in that order and stirred for 20 minutes. Successively, aqueous sodium hydroxide solution (5 M, 0.2 mL) was added and stirred overnight. After confirming the disappearance of the raw material by thin layer chromatography, acetic acid (200 μL) was added to stop the reaction, and the compound h (26.5 mg) was obtained as a white powder by purifying it by high performance liquid chromatography. HRMS (ESI-TOF) Calcd for C 30 H 37 79 BrN2NaO9S [M+Na] + : 703.13008; Found: 703.12760, Calcd for C 30 H 37 81 BrN2NaO9S [M+Na]+ : 705.12804; Found: 705.12621, Calcd for C 30 H 36 79 BrN2NaO9S [M-H+2Na] + : 725.11203; Found: 725.10900, Calcd for C 30 H 36 81 BrN2NaO9S [M-H+2Na] + : 727.10998; Found: 727.10862.

[0082] [Measurement of sialidase activity of influenza A virus] The sialidase activity of influenza A virus was measured by preparing influenza A virus neuraminidase (NA) expressing cells that express influenza A virus sialidase, and measuring the sialidase activity when each compound was added to the NA expressing cells. The specific measurement method is as follows.

[0083] HEK293T cells, which are human fetal kidney cells, were used. HEK293T cells were cultured in D-MEM medium (Dulbecco's modified essential medium) supplemented with 10% fetal bovine serum (FBS) at 37°C under 5% CO2 conditions. The plasmid used was pCAGGS-HK68NA, a plasmid in which the neuraminidase (NA) sequence of influenza A virus A / Hong Kong / 1 / 1968 H3N2 strain was incorporated into the pCAGGS vector. Compound a (positive control) and each of the compounds b to h to be screened were dissolved in DMSO (dimethyl sulfoxide) to prepare a solution with a concentration of 100 mM, and stored at -30°C.

[0084] First, HEK293T cells were seeded in each well of a 6-well plate and cultured overnight at 5% CO2 and 37°C to a state of 70% confluence. According to the protocol of the transfection reagent (TransIT (registered trademark)-293 Reagent, manufactured by Takara Bio Inc.), HEK293T cells were transfected with the above-mentioned plasmid pCAGGS-HK68NA (derived from influenza A virus: Hong Kong / 1 / 1968 H3N2 strain) using 2.5 μg / well, and cultured at 5% CO2 and 37°C for 48 hours. After removing the medium, 1 mL of phosphate buffer (131 mM NaCl, 14 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, pH 7.2, hereinafter referred to as PBS) was added to each well, the cells were suspended, and then centrifuged (4°C, 800 × g, 10 minutes) to remove the supernatant. The cells precipitated by centrifugation were suspended in 100 mM acetate buffer (pH 4.5) to prepare an NA-expressing cell suspension.

[0085] 50 μL of the NA-expressing cell suspension prepared as described above was added to each well of a 96-well black plate and allowed to stand at 37 °C for 5 minutes. Each compound a-h was diluted to 100 μM with 100 mM acetate buffer (pH 4.5) and centrifuged (4 °C, 10,000 × g, 10 minutes), and 50 μL of the supernatant was added to each well and mixed with the NA-expressing cell suspension in the well (final concentration of each compound was 50 μM). After mixing, the mixture was reacted at 37 °C for 20 minutes. Using a microplate reader (Infinite (registered trademark) M200, manufactured by Tecan Japan Co., Ltd.), the fluorescence intensity of BTP3 released by reaction with sialidase was measured three times independently at an excitation wavelength of 372 nm and a measurement wavelength of 526 nm (Ex / Em = 372 nm / 526 nm). Blank was the fluorescence intensity in cells transfected with the empty plasmid vector pCAGGS·MCS. Sialidase activity was measured three times independently, and the relative fluorescence intensity was calculated by subtracting the blank from the fluorescence intensity of each compound. The fluorescence intensity of the compound a (BTP3-Neu5Ac) used as a positive control was set as 100%, and the mean value ± standard error was used.

[0086] The results are shown in Figure 1. The horizontal axis of Figure 1 indicates compound No., and the vertical axis indicates relative sialidase activity. The present inventors discovered compound b (22-001a) as a substrate compound highly reactive to influenza A virus sialidase. The sialidase activity of compound b (22-001a) was approximately 70% of the sialidase activity of BTP3-Neu5Ac (compound a) used as a positive control, and the compound also had sufficient fluorescence intensity to be applicable as a virus detection reagent, particularly as a fluorescent imaging agent.

[0087] [Example 2] 2. Examination of reactivity to sialidases from other virus species In Example 1, compound b (22-001a) was found to have high reactivity to influenza A virus sialidase and to be capable of detecting influenza A virus sialidase. A test was carried out to confirm whether the compound b (22-001a) is a compound having similar reactivity to sialidases of other virus species. Specifically, sialidase-expressing cells of various viruses were prepared, and the sialidase activity was measured when compound b was added to the sialidase-expressing cells. In this Example, the following virus species were selected: mumps virus (hereinafter also referred to as "MuV") 13V165E2 strain, human parainfluenza virus serotype 3 (hereinafter also referred to as "hPIV3") C243 strain, Newcastle disease virus (hereinafter also referred to as "NDV") D26 strain, and influenza A virus (hereinafter also referred to as "IAV") A / Hong Kong / 1 / 1968 H3N2 strain also used in Example 1, and these sialidase-expressing cells were prepared. Specifically, the following plasmids were used.

[0088] pCAGGS-MuVHN: A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of MuV 13V165E2 strain in the pCAGGS vector. pCAGGS-hPIV3HN: A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of hPIV3 C243 strain in the pCAGGS vector. pCAGGS-NDV-D26HN: A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of NDV D26 strain in the pCAGGS vector. pCAGGS-HK68NA: a plasmid in which the neuraminidase (NA) sequence of IAV A / Hong Kong / 1 / 1968 H3N2 strain was incorporated into the pCAGGS vector (the same as that used in Example 1).

[0089] Cells expressing sialidases of various viruses were prepared in the same manner as in Example 1, except that the plasmids used in the sialidase activity test in Example 1 were replaced with the four types of plasmids mentioned above. Using the same materials and methods as in Example 1, sialidase activity was measured when compound a (BTP3-Neu5Ac) or compound b (22-001a) was added to the cells expressing sialidases of various viruses. Blank was the fluorescence intensity in cells transfected with the empty plasmid vector pCAGGS·MCS. Sialidase activity was expressed as the average value ± standard error of the value obtained by subtracting Blank from the fluorescence intensity of each compound in three independent measurements.

[0090] In addition, instead of various viral sialidase expressing cells, sialidase derived from Arthrobacter ureafaciens, a bacterium of the Arthrobacter genus, was used to measure the sialidase activity when compound a (BTP3-Neu5Ac) or compound b (22-001a) was added. Sialidase derived from Arthrobacter ureafaciens (product number: 10269611001, manufactured by Merck Ltd.) was used after adjusting to 0.1 U / mL with 100 mM acetate buffer (pH 4.5). After adding compound a or b, the fluorescence intensity was measured when reacting for 20 minutes at 37°C.

[0091] The results are shown in the graph in Figure 2. The horizontal axis of Figure 2 shows the name of the virus or bacteria from which each sialidase was derived, and the vertical axis shows the sialidase activity. The white columns show the results for the positive control compound a (BTP3-Neu5Ac), and the black columns show the results for compound b (22-001a). The results show that the positive control compound a (BTP3-Neu5Ac) is a sialidase substrate that reacts with sialidases derived from all virus species and Arthrobacter, while compound b (22-001a) is a sialidase substrate that reacts specifically with influenza A virus sialidase. From this, it was revealed that compound b (22-001a) is a substrate compound with excellent specificity for influenza A virus sialidase, a compound that can specifically detect influenza A virus sialidase and determine the presence or absence of influenza A virus, and a compound that reacts specifically with influenza A virus sialidase to produce a fluorescent substance with sufficient fluorescence intensity.

[0092] [Example 3] 3. Study of reactivity of influenza A viruses with different NA subtypes or other virus species to sialidases In Example 2, it was revealed that compound b (22-001a) can specifically detect influenza A virus sialidase. The reactivity of compound b (22-001a) against sialidase of other virus species including influenza A virus and influenza B virus with different NA subtypes was examined. In this Example, the final concentration of compound b in the reaction solution was set to 25 μM, 50 μM, and 100 μM, and it was also examined whether concentration-dependent reactivity was observed. Specifically, as in Example 2 described above, sialidase-expressing cells of various viruses were prepared, and the sialidase activity was measured when compound b was added to the sialidase-expressing cells. In this example, the influenza A virus (hereinafter also referred to as "IAV") A / Hong Kong / 1 / 1968 H3N2 strain, influenza A virus A / PR / 8 / 1934 H1N1 strain, influenza B virus (hereinafter also referred to as "IBV") B / Lee / 1940 strain, mumps virus (hereinafter also referred to as "MuV") 13V165E2 strain, human parainfluenza virus serotype 1 (hereinafter also referred to as "hPIV1") C35 strain, and human parainfluenza virus serotype 3 (hereinafter also referred to as "hPIV3") C243 strain, which were also used in Examples 1 and 2, were selected as virus species, and these sialidase-expressing cells were prepared. Specifically, the following plasmids were used.

[0093] A plasmid in which the neuraminidase (NA) sequence of IAV A / Hong Kong / 1 / 1968 H3N2 strain was incorporated into the pCAGGS vector (the same as that used in Examples 1 and 2). A plasmid containing the neuraminidase (NA) sequence of IAV A / PR / 8 / 1934 H1N1 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IBV B / Lee / 1940 strain in the pCAGGS vector A plasmid in which the hemagglutinin-neuraminidase (HN) sequence of MuV 13V165E2 strain was incorporated into the pCAGGS vector (the same as that used in Example 2). A plasmid in which the hemagglutinin-neuraminidase (HN) sequence of hPIV1 C35 strain was incorporated into the pCAGGS vector (the same as that used in Example 2) A plasmid in which the hemagglutinin-neuraminidase (HN) sequence of hPIV3 C243 strain was incorporated into the pCAGGS vector (the same as that used in Example 2)

[0094] HEK293T cells, which are human fetal kidney cells, were used. HEK293T cells were cultured in D-MEM (Dulbecco's modified essential medium) supplemented with 10% fetal bovine serum (FBS) at 37°C under 5% CO2 conditions. First, 7.5 × 10 HEK293T cells were placed in each well of a 6-well plate. 5 The cells were seeded at 1000 x 1000 cells / well and cultured overnight at 5% CO2 and 37°C to a confluent state of 80-90%. According to the protocol of the transfection reagent (TransIT (registered trademark)-293 Reagent, manufactured by Takara Bio Inc.), HEK293T cells were transfected with 2.5 μg / well of each of the above-mentioned plasmids and cultured at 5% CO2 and 37°C for 72 hours. After removing the medium, 1 mL of phosphate buffer (131 mM NaCl, 14 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, pH 7.2, hereinafter referred to as PBS) was added to each well, the cells were suspended, and the supernatant was removed by centrifugation (4°C, 1000 x g, 10 minutes). The cells precipitated by centrifugation were suspended in 100 mM acetate buffer (pH 6.0 when the sialidase to be measured was IAV or IBV, and pH 4.5 when the sialidase was MuV, hPIV1, or hPIV3) to prepare NA-expressing cell suspensions for each virus species.

[0095] Compound b was dissolved in DMSO in advance to a concentration of 100 mM in stock solution, and diluted to a concentration of 1 mM with 100 mM acetate buffer (pH 6.0 when the sialidase to be measured is IAV and IBV, pH 4.5 when the sialidase to be measured is MuV, hPIV1 and hPIV3). After centrifugation (4°C, 10,000 x g, 10 minutes), the supernatant was collected and serially diluted to a final concentration of compound b of 25 μM, 50 μM and 100 μM. 40 μL of the NA-expressing cell suspension prepared as described above and 10 μL of diluted solution of compound b (final concentration of compound b: 25 μM, 50 μM and 100 μM) were added to each well of a 96-well black plate on ice, and the mixture was mixed on a plate mixer for 5 seconds, and then reacted at 37°C for 20 minutes. At the end of the reaction, 100 mM sodium carbonate buffer (pH 10.7) was added at 50 μL / well on ice. Compound a (BTP3-Neu5Ac), a positive control, was also treated in the same manner as compound b. Using a microplate reader (Infinite (registered trademark) M200, Tecan Japan Co., Ltd.), the fluorescence intensity of BTP3 released by the reaction with sialidase was measured three times independently at an excitation wavelength of 372 nm and a measurement wavelength of 526 nm (Ex / Em = 372 nm / 526 nm). Blank was the fluorescence intensity in cells transfected with the empty plasmid vector pCAGGS·MCS. Sialidase activity was expressed as the average value ± standard error of the value obtained by subtracting Blank from the fluorescence intensity of compound b in three independent measurements.

[0096] The results are shown in the graph of FIG. 3. The horizontal axis of FIG. 3 indicates the concentration of compound b and compound a as a positive control. The white column indicates the result of the positive control compound a (BTP3-Neu5Ac), and the black column indicates the result of compound b (22-001a). According to the result, it was found that compound b (22-001a) reacts with both types of sialidase of influenza A virus whose NA subtype is N1 and N2, but does not react at all with sialidase of other virus species including influenza B virus. It was also found that the reactivity of compound b with influenza A virus sialidase is concentration-dependent. From these results, it was revealed that compound b (22-001a) is a substrate compound with excellent specificity for influenza A virus sialidase, is a compound that can specifically detect influenza A virus sialidase and discriminate the presence or absence of influenza A virus, and is a compound that generates a fluorescent substance with sufficient fluorescence intensity by specifically reacting with influenza A virus sialidase.

[0097] [Example 4] 4. Fluorescence imaging of virus-infected cells (1) In Examples 2 and 3, the compound b (22-001a) was used to perform fluorescence imaging of influenza A virus-infected cells, which was confirmed to be capable of specifically detecting influenza A virus sialidase. In addition, in order to confirm that compound b does not perform fluorescence imaging of cells infected with viruses other than influenza A virus, similar tests were performed on cells infected with other viruses. In this Example, influenza A virus A / Hong Kong / 1 / 1968 H3N2 strain, mumps virus 13V165E2 strain, human parainfluenza virus serotype 1 (hereinafter also referred to as "hPIV1") C35 strain, human parainfluenza virus serotype 3 C243 strain, and Newcastle disease virus D26 strain were selected as virus species, and cells infected with these viruses were prepared.

[0098] The host cells used were MDCK cells derived from dog kidney for IAV, Vero cells derived from African green monkey kidney for MuV, and LLC-MK2 cells derived from rhesus monkey kidney for NDV, hPIV1, and hPIV3. Each cell was cultured in MEM medium (minimum essential medium) containing 5% FBS at 5% CO2 and 37°C.

[0099] The cells were seeded in each well of a 48-well plate and cultured overnight at 5% CO2 and 37°C to a confluent state. After washing the cells with 200 μL / well of PBS, 200 μL / well of each virus-serum-free medium (Hybridoma-SFM, manufactured by Thermo Fisher Scientific Co., Ltd., hereinafter referred to as SFM) suspension was added so that each virus was 200 focus-forming units (hereinafter referred to as FFU) / well, and the cells were left to stand at 5% CO2 and 37°C for 1 hour to infect the corresponding host cells with the virus. After washing the cells with 200 μL / well of PBS, the medium was replaced with 200 μL / well of SFM and cultured at 5% CO2 and 37°C. Note that IAV, MuV and NDV-infected cells were cultured for 24 hours, and hPIV1 and hPIV3-infected cells were cultured for 48 hours.

[0100] On the day of observation, compound a (BTP3-Neu5Ac) or compound b (22-001a) was diluted to 50 μM with SFM. Each compound was diluted to 100 μM as the SFM dilution solution for addition to MuV-infected cells, and SFM was prepared with 1N HCl to pH 4.5 as the SFM dilution solution for addition to hPIV1-infected cells and hPIV3-infected cells. After centrifugation (4°C, 10,000×g, 10 minutes), the supernatant was collected to separate the nonspecifically cleaved fluorescent substance. After washing each infected cell with 200 μL / well of PBS, 200 μL / well of SFM supernatant containing compound a or compound b was added and reacted at 37°C for 30 minutes. Each infected cell was washed with 200 μL / well of PBS, replaced with 200 μL / well of PBS, and the fluorescent image was observed using a fluorescence microscope (model number: BZ-X700, Keyence Corporation) with a custom-made BTP filter (excitation wavelength: 360 / 40 nm, absorption wavelength: 525 / 50 nm, dichroic mirror wavelength: 400 nm). The results are shown in Figure 4.

[0101] This result showed that compound b (22-001a) can perform histochemical fluorescent imaging of influenza A virus-infected cells. In addition, the positive control compound a (BTP3-Neu5Ac) was capable of fluorescent imaging of cells infected with all virus species, whereas compound b (22-001a) performed fluorescent imaging of only influenza A virus-infected cells. This demonstrated that compound b (22-001a) is a compound capable of specifically fluorescent imaging of influenza A virus, and is a compound capable of specifically detecting influenza A virus-infected cells and determining the presence or absence of influenza A virus.

[0102] [Example 5] 5. Fluorescence imaging of virus-infected cells (2) In this example, a plurality of different influenza A virus strains and influenza B virus strains, including the virus strain used in Example 4, were used as influenza viruses, and fluorescent imaging of cells infected with these influenza virus strains was performed. In this example, the following IAV strains with different subtypes or hosts were selected: the 1968 pandemic strain A / Hong Kong (HK) / 1 / 1968 H3N2 strain (the same as that used in Example 4), the widely used laboratory strain A / PR / 8 / 1934 H1N1 strain, the 2009 novel pandemic strain A / Shizuoka / 830 / 2009 H1N1 strain, and the avian influenza virus A / duck / HK / 313 / 4 / 1978 H5N3 strain; and the influenza B virus strain B / Lee / 1940 strain, and cells infected with these viruses were prepared.

[0103] In the preparation of virus-infected cells in Example 4, IAV-infected cells and IBV-infected cells were prepared using canine kidney-derived MDCK cells as host cells in the same manner as in Example 4, except that the viruses used were replaced with the above-mentioned five types of viruses. Fluorescence imaging of various viruses using compound b (22-001a) was performed using the same materials and methods as in Example 4. The results are shown in Figure 5.

[0104] According to these results, compound b (22-001a) was capable of fluorescent imaging of cells infected with any influenza A virus strain. On the other hand, no fluorescence was observed at all in cells infected with influenza B virus. This shows that compound b (22-001a) is capable of fluorescent imaging of influenza A viruses, regardless of the specific strain of influenza A virus, even if the subtype or host is different, and can detect the presence or absence of influenza A virus. Furthermore, since compound b fluorescently images only influenza A viruses, even if they are the same influenza virus, it was revealed that compound b can be used as a detection reagent to distinguish between influenza A viruses and influenza B viruses.

[0105] [Example 6] 6. Study on isolation of influenza A virus strains (1) In this example, a method for isolating a virus strain was investigated by fluorescent imaging of influenza A virus foci (virus-infected cell populations). In this example, the IAV A / Hong Kong / 1 / 1968 H3N2 strain, MuV 13V165E2 strain, hPIV3 C243 strain, and NDV D26 strain were selected as virus species, and cells infected with these viruses were prepared.

[0106] The host cells used were MDCK cells derived from dog kidney for IAV, Vero cells derived from African green monkey kidney for MuV, and LLC-MK2 cells derived from rhesus monkey kidney for NDV and hPIV3. Each cell was cultured in MEM medium containing 5% FBS at 5% CO2 and 37°C.

[0107] Each type of cell was seeded in each well of a 6-well plate and cultured until it became confluent. After washing each cell with 2 mL / well of PBS, 1 mL / well of each virus-SFM suspension was added so that each virus was 1000 FFU / well, 100 FFU / well, or 10 FFU / well, and the cells were incubated at 5% CO2 and 37°C for 1 hour to infect the corresponding host cells with the virus. On the other hand, 1 mL / well of SFM was added to the wells of uninfected cells and incubated at 5% CO2 and 37°C for 1 hour. After washing the cells with 2 mL / well of PBS, the medium was replaced with 4 mL / well of 0.8% agar (Bacto Agar, Becton Dickinson Japan Co., Ltd.)-SFM suspension containing 2 μg / mL of acetylated trypsin, and after the agar medium solidified, the cells were incubated at 5% CO2 and 37°C for 96 hours. 200 μL / well of SFM containing 2 mM compound b (22-001a) was added to the agar medium, and IAV-infected cells, MuV-infected cells, and NDV-infected cells were reacted at 37°C for 4 hours, and hPIV3-infected cells were reacted at 37°C for 6 hours. The foci were irradiated with 365 nm ultraviolet light on a transilluminator and fluorescently imaged. The results are shown in Figure 6.

[0108] These results show that compound b (22-001a) can specifically image influenza A virus foci with fluorescent imaging. Among these, an independent focus from which a virus strain could be isolated was fluorescently imaged from an agar medium with a virus infectivity of 10 FFU / mL. When the fluorescent focus indicated by the white arrow in Figure 6 was picked up and infected into a new host cell, the virus strain could be isolated. This shows that compound b (22-001a) can image influenza A virus foci with live imaging, and that the virus strain can be easily isolated by picking up the live-imaged focus.

[0109] [Example 7] 7. Study on isolation of influenza A virus strains (2) Based on the results of Example 6 described above, in this Example, an investigation was conducted to determine whether influenza A virus could be isolated from samples containing a mixture of different virus species. In this Example, the IAV A / Hong Kong / 1 / 1968 H3N2 strain and the hPIV1 C35 strain were selected as virus species, and IAV-infected cells, hPIV1-infected cells, and cells infected with both IAV and hPIV1 were prepared.

[0110] Rhesus monkey kidney-derived LLC-MK2 cells were used as host cells. Cells were cultured in 5% FBS-containing MEM medium at 5% CO2 and 37°C. LLC-MK2 cells were seeded in each well of a 6-well plate and cultured until confluent. After washing the cells with 2mL / well of PBS, 2mL / well of each virus-SFM suspension was added so that IAV and hPIV1 were each 10FFU / well, or each virus alone was 10FFU / well, and the cells were left to stand at 5% CO2 and 37°C for 1 hour to infect the LLC-MK2 cells with the virus. After washing the cells with 2mL / well of PBS, the cells were replaced with 4mL / well of 0.8% agar-SFM suspension containing 2μg / mL acetylated trypsin, and after the agar medium solidified, the cells were cultured at 5% CO2 and 37°C for 96 hours. On the agar medium, 200 μL / well of SFM containing 1 mM compound a (BTP3-Neu5Ac) or 200 μL / well of SFM containing 2 mM compound b (22-001a) was added and reacted at 37 ° C. for 7 hours. Although compound b can fluorescently image IAV foci at 37 ° C. with a reaction time of 4 hours (see Example 6), the reaction time was unified to 7 hours because fluorescent imaging of hPIV1 foci using compound a (BTP3-Neu5Ac) used as a positive control took 7 hours. After 7 hours of reaction, 365 nm ultraviolet light was irradiated on a transilluminator to fluorescently image the virus foci. The results are shown in FIG. 7.

[0111] According to this result, it was shown that the positive control compound a (BTP3-Neu5Ac) fluorescently images both IAV and hPIV1 foci, whereas compound b fluorescently images only IAV foci. Among these, in cells infected with both IAV and hPIV1 viruses (IAV+hPIV), when the fluorescent foci fluorescently imaged by compound b were picked up and infected into new host cells, IAV strains could be isolated. From this, it was revealed that compound b (22-001a) can live image only influenza A virus foci even in samples containing a mixture of different virus species, and that only influenza A virus strains can be selectively isolated from samples containing a mixture of virus species.

[0112] [Example 8] 8. Examination of the reactivity of compound b (22-001a) derivatives against sialidases of influenza viruses, etc. In the above-mentioned Examples 1 to 7, it was shown that compound b (22-001a) can specifically detect influenza A virus. Therefore, in this Example, derivatives of compound b were prepared, and the reactivity and specificity of the derivatives to sialidase of influenza viruses and the like were examined. The compounds used in this examination are shown in Table 2 below. Among the compounds shown in Table 2, compound k and compound l (l) are compounds newly prepared as derivatives of compound b. The compound b shown in Table 2 below was synthesized in Example 1.

[0113] [Table 2]

[0114] Compound k (23-139b) and compound l (23-136b4) shown in Table 2 were synthesized based on the following formula. The compounds (including intermediates) obtained by synthesis were confirmed to be the target products by high-resolution mass spectrometry (HRMS). High-resolution mass spectrometry was performed using AccuTOF (JMS-T100LC) manufactured by JEOL Ltd., and was measured in positive mode by connecting an ES (electrospray ion source).

[0115] [ka]

[0116] [Synthesis of compound k (23-139b)] A sodium methoxide solution (5M in MeOH, 4.0mL) was added to a methanol solution (150mL) of 14.93g (19.2mmol) of known compound X (see PLOS ONE, 2014, Vol. 9, No. 1, e81941) and stirred at room temperature for 2 hours. Sodium methoxide (1.5mL) was added twice every hour while checking the thin layer chromatography. After confirming the disappearance of the raw material, acetic acid (1.5mL) was added to stop the reaction. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (100% ethyl acetate) to obtain the tetrahydroxy compound Y (6.68g, 57% yield) as a white solid. HRMS (ESI-TOF) Calcd for C 25 H 27 79 BrN2NaO9S [M+Na] + : 633.05183; Found: 633.05172, Calcd for C 25 H 27 81 BrN2NaO9S [M+Na] + : 635.04979; Found: 635.05115.

[0117] Subsequently, a solution of 2-butanone (3 mL), trimethyl orthoformate (1 mL), and camphorsulfonic acid (CSA; 76 mg, 0.4 mmol) was stirred at 70° C. for 17 hours to prepare a 2-butanone dimethyl acetal solution. The obtained solution (2 mL) was added to a solution of compound Y (612 mg) in DMF (4 mL). The reaction was monitored by TLC, and after 2 hours, paratoluenesulfonic acid monohydrate (100 mg) was added and stirred for another 30 minutes. The reaction was stopped by adding an aqueous sodium bicarbonate solution, extracted with ethyl acetate, and the organic layer was washed three times with water and once with saturated saline. The organic layer was dried over sodium sulfate, the drying agent was filtered off, and the solvent was distilled off under reduced pressure to obtain a methyl ester intermediate. The obtained methyl ester intermediate was dissolved in methanol (2 mL), and an aqueous sodium hydroxide solution (2.5 M, 1.4 mL) was added and stirred for 15 hours. The reaction mixture was neutralized with acetic acid and purified by high performance liquid chromatography to obtain compound k (235 mg, yield 36%) as a colorless amorphous substance. HRMS (ESI-TOF) Calcd for C 28 H 32 79 BrNO9S [M+H] + : 651.10119; Found: 651.09970, Calcd for C 28 H 32 81 BrNO9S [M+H] + : 653.09914; Found: 653.09785, Calcd for C 28 H 31 79 BrN2NaO9S [M+Na] + : 673.08313; Found: 673.08028, Calcd for C 28 H 31 81 BrN2NaO9S [M+Na] + : 675.08109; Found: 675.07871.

[0118] [Synthesis of compound l (23-136b4)] Compound l was synthesized as follows by the same method as the synthesis method of compound k described above. In the synthesis route from compound Y, which is a tetrahydroxy compound, a solution of 3-propanone (3 mL), trimethyl orthoformate (1 mL), and camphorsulfonic acid (CSA; 76 mg, 0.4 mmol) was stirred at 70 ° C. for 17 hours to prepare a 3-propanone dimethyl acetal solution. The obtained solution (2 mL) was added to a solution of compound Y (612 mg) in acetonitrile (2 mL) and stirred for 1.5 hours. Triethylamine (500 μL) was added to stop the reaction, and the solvent was distilled off under reduced pressure. Methanol (2 mL) and an aqueous sodium hydroxide solution (2.5 M, 1.4 mL) were added to the obtained residue and stirred for 19 hours. Acetic acid was added to the reaction solution to neutralize it, and it was purified using high-performance liquid chromatography to obtain compound l (113 mg, 17% yield) as a colorless amorphous substance. HRMS (ESI-TOF) Calcd for C 29 H 34 79 BrNO9S [M+H] + : 665.11684; Found: 665.11673, Calcd for C 29 H 34 81 BrNO9S [M+H] + : 667.11479; Found: 667.11515, Calcd for C 29 H 33 79 BrN2NaO9S [M+Na] + : 687.09878; Found: 687.10009, Calcd for C 29 H 33 81 BrN2NaO9S [M+Na] + : 689.09674; Found: 689.09816.

[0119] [Study of reactivity of various viruses to sialidase] The sialidase expressing cells of various viruses were prepared by the same method as in Example 3, and the reactivity was examined by measuring the sialidase activity when compound k (23-139b), compound l (23-136b4), compound a (positive control; BTP3-Neu5Ac) and compound b (22-001a) were added to the sialidase expressing cells. In this example, four types of influenza A viruses were selected as the virus species: A / PR / 8 / 1934 H1N1 strain, A / Shizuoka / 838 / 2009 H1N1 strain, A / Shizuoka / 738 / 2008 H1N1 strain and A / Memphis / 1 / 1971 H3N2 strain. In addition, the following viruses were selected as non-IAV viruses: influenza B virus (IBV) B / Lee / 1940 strain, mumps virus (MuV) 13V165E2 strain, human parainfluenza virus serotype 1 (hPIV1) C35 strain, and human parainfluenza virus serotype 3 (hPIV3) C243 strain. Specifically, the following plasmids were used to express sialidase from various viruses.

[0120] A plasmid containing the neuraminidase (NA) sequence of IAV A / PR / 8 / 1934 H1N1 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IAV A / Shizuoka / 838 / 2009 H1N1 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IAV A / Shizuoka / 738 / 2008 H1N1 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IAV A / Memphis / 1 / 1971 H3N2 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IBV B / Lee / 1940 strain in the pCAGGS vector A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of MuV 13V165E2 strain in the pCAGGS vector A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of hPIV1 C35 strain in the pCAGGS vector A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of hPIV3 C243 strain in the pCAGGS vector

[0121] The sialidase activity of various viruses was measured by the same method as in Example 3, except that the compound added to the NA-expressing cell suspension was replaced with compound k (23-139b) and compound l (23-136b4). In addition, in this example, the final concentration of each compound in the reaction solution was set to 25 μM, 50 μM, 100 μM, and 200 μM, and it was also examined whether concentration-dependent reactivity was observed.

[0122] The results are shown in the graphs of Figures 8 to 11. The vertical axis of each graph is the fluorescence intensity indicating the sialidase activity, and the horizontal axis is the final concentration (μM) of the compound added. According to these results, it was found that compound k (23-139b) is a sialidase substrate that reacts with all of the sialidases of influenza A virus strains A / PR / 8 / 1934 H1N1, A / Shizuoka / 838 / 2009 H1N1, A / Shizuoka / 738 / 2008 H1N1, and A / Memphis / 1 / 1971 H3N2 (Figures 8 and 10). In addition, in the above-mentioned Example 3, it was revealed that compound b does not react with influenza B virus sialidase, but compound k was revealed to be a sialidase substrate that also reacts with influenza B virus sialidase, as shown in Figure 9. Furthermore, compound k reacted slightly with mumps virus sialidase, but did not react with human parainfluenza virus serotypes 1 and 3 sialidases (Figure 11). On the other hand, compound l (23-136b4) hardly reacted with various viral sialidases, and was not recognized as a sialidase substrate. From these results, it was revealed that compound k (23-139b) is a substrate compound with excellent specificity for influenza A virus and influenza B virus sialidases, and is a compound that can specifically detect influenza A and B virus sialidases and distinguish the presence or absence of influenza A or B virus.

[0123] [Example 9] 9. Fluorescence imaging of virus-infected cells (3) In this example, the compound k (23-139b) was used to perform fluorescence imaging of influenza A virus-infected cells and influenza B virus-infected cells. In addition, in order to confirm that compound k does not perform fluorescence imaging of cells infected with virus species other than influenza A and B viruses, similar tests were performed on cells infected with other virus species. In this example, the virus species used were A / PR / 8 / 1934 H1N1 strain, A / Shizuoka / 738 / 2008 H1N1 strain, and A / Memphis / 1 / 1971 H3N2 strain for influenza A virus (IAV), and B / Lee / 1940 strain for influenza B virus (IBV). In addition, the mumps virus (MuV) 13V165E2 strain, human parainfluenza virus serotype 1 (hPIV1) C35 strain, and human parainfluenza virus serotype 3 (hPIV3) C243 strain were selected as other virus species, and cells infected with these viruses were prepared.

[0124] The host cells used were MDCK cells derived from dog kidney for IAV and IBV, Vero cells derived from African green monkey kidney for MuV, and LLC-MK2 cells derived from rhesus monkey kidney for hPIV1 and hPIV3. Each cell was cultured in MEM medium (minimum essential medium) containing 5% FBS at 5% CO2 and 37°C.

[0125] Cells were plated at 2 x 10 in each well of a 96-well plate. 4The cells were seeded at 100 μL / well so that each virus was 100 focus-forming units (FFU) / well, and then cultured at 5% CO2 and 37°C overnight to reach a confluent state. After washing the cells with 50 μL / well of PBS, 50 μL / well of each virus-serum-free medium (Hybridoma-SFM, manufactured by Thermo Fisher Scientific Co., Ltd., hereinafter referred to as SFM) was added, and the cells were left to stand at 5% CO2 and 37°C for 1 hour to infect the corresponding host cells with the virus. After washing the cells with 50 μL / well of PBS, the medium was replaced with 50 μL / well of SFM and cultured at 5% CO2 and 37°C. Note that IAV, IBV and MuV-infected cells were cultured for 24 hours, and hPIV1 and hPIV3-infected cells were cultured for 48 hours.

[0126] Just before observation, compound k (23-139b) or the positive control compound a (BTP3-Neu5Ac) was diluted to 200 μM with SFM (pH 7.4). As the SFM dilution solution for addition to hPIV1-infected cells and hPIV3-infected cells, SFM was prepared with 1N HCl at pH 4.5 for each use. After centrifugation (4°C, 10,000 x g, 10 minutes), the supernatant was collected to separate the nonspecifically cleaved fluorescent substance. The SFM on each infected cell was removed on ice, replaced with SFM supernatant containing 200 μM compound k or compound a, and reacted at 37°C for 20 minutes. At the end of the reaction, the SFM supernatant containing compound k or compound a was removed on ice, and each infected cell was washed with 50 μL / well of PBS and then replaced with 50 μL / well of SFM. Fluorescence images were observed using a fluorescence microscope (model number: BZ-X700, Keyence Corporation) with a custom-made BTP filter (excitation wavelength: 360 / 40 nm, absorption wavelength: 525 / 50 nm, dichroic mirror wavelength: 400 nm) (objective lens 20x, shooting settings: high sensitivity mode, exposure time 1 / 4 sec). The results are shown in Figure 12.

[0127] According to this result, it was shown that compound k (23-139b) can perform histochemical fluorescence imaging of influenza A virus-infected cells. In addition, clear fluorescence was observed in influenza B virus-infected cells with compound k, indicating that histochemical fluorescence imaging of influenza B virus-infected cells is also possible. In addition, the positive control compound a (BTP3-Neu5Ac) can perform fluorescence imaging of all virus-infected cells, whereas compound k (23-139b) performed fluorescence imaging of only influenza A and B virus-infected cells. From this, it was revealed that compound k (23-139b) is a compound capable of specifically performing fluorescence imaging of influenza A and B viruses, and is a compound capable of specifically detecting influenza A and B virus-infected cells and discriminating the presence or absence of influenza A or B viruses.

[0128] [Example 10] 10. Search for compounds capable of distinguishing sialidases from influenza A viruses with different NA subtypes Influenza A viruses are classified into subtypes based on the combination of 16 types of hemagglutinin (HA) and 9 types of neuraminidase (NA). Among these, the NA subtypes of influenza A viruses that infect humans are mainly N1 and N2, so a detection reagent capable of distinguishing between the two is desired. Therefore, among the NA subtypes of influenza A viruses, a study was conducted on compounds capable of distinguishing between N1 and N2. The compounds used in this study are shown in Table 3 below. Compound c (22-002b_i), compound e (22-002b_t), compound f (22-005b_c), and compound g (22-005b_b) shown in Table 3 below were synthesized in Example 1.

[0129] [Table 3]

[0130] [Study of reactivity of various viruses to sialidase] In the same manner as in Example 3, sialidase-expressing cells of various viruses were prepared, and the reactivity was examined by measuring the sialidase activity when compound c (22-002b_i), compound e (22-002b_t), compound f (22-005b_c), compound g (22-005b_b), and compound a (positive control; BTP3-Neu5Ac) were added to the sialidase-expressing cells. In this example, the A / PR / 8 / 1934 H1N1 strain and the A / Shizuoka / 738 / 2008 H1N1 strain were used as the virus species for influenza A viruses with NA subtype N1. In addition, the A / Memphis / 1 / 1971 H3N2 strain was used as the influenza A virus with NA subtype N2. In addition, the influenza B virus (IBV) B / Lee / 1940 strain was selected as the virus species other than IAV. Specifically, the following plasmids were used for expressing sialidase from various viruses:

[0131] A plasmid containing the neuraminidase (NA) sequence of IAV A / PR / 8 / 1934 H1N1 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IAV A / Shizuoka / 738 / 2008 H1N1 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IAV A / Memphis / 1 / 1971 H3N2 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IBV B / Lee / 1940 strain in the pCAGGS vector

[0132] The sialidase activity of various viruses was measured in the same manner as in Example 8, except that the compounds added to the NA-expressing cell suspension were changed to the compounds shown in Table 3.

[0133] The results are shown in the graph in Figure 13. The vertical axis of each graph is the fluorescence intensity indicating sialidase activity, and the horizontal axis is the final concentration (μM) of each compound added. These results show that compound c (22-002b_i) reacts with the sialidase of influenza A virus with NA subtype N1, but its reaction with the sialidase of influenza A virus with NA subtype N2 is significantly weaker, and it does not react at all with the sialidase of influenza B virus. On the other hand, compound e (22-002b_t) and compound g (22-005b_b) did not react with any influenza virus sialidase, and compound f (22-005b_c) reacted with all kinds of influenza virus sialidases, similar to compound a (positive control; BTP3-Neu5Ac). This indicates that compound c (22-002b_i) is a compound capable of discriminating between sialidase of influenza A virus with NA subtype N1 and sialidase of influenza A virus with NA subtype N2. As shown in the results of Example 13 described later (FIG. 16), compound c (22-002b_i) also reacts with MuV sialidase and hPIV sialidase, and therefore cannot specifically detect sialidase of influenza A virus with NA subtype N1. However, it is preferable to perform screening using compound b (22-001a) or compound k (23-139b) capable of specifically detecting influenza A virus sialidase, and then perform detection using compound c (22-002b_i) to discriminate the NA subtype.

[0134] [Example 11] 11. Fluorescence imaging of virus-infected cells (4) In this example, fluorescent imaging of influenza A virus-infected cells with NA subtype N1 and influenza A virus-infected cells with NA subtype N2 was performed using compound c (22-002b_i), which was confirmed to be a compound capable of distinguishing between sialidase of influenza A virus with NA subtype N1 and sialidase of influenza A virus with NA subtype N2 in Example 10. In this example, A / Shizuoka / 738 / 2008 H1N1 strain was used as the influenza A virus with NA subtype N1, and A / Memphis / 1 / 1971 H3N2 strain was used as the influenza A virus with NA subtype N2, and cells infected with these viruses were prepared.

[0135] Influenza A virus-infected cells were prepared in the same manner as in Example 9, except that the viruses used in the preparation of virus-infected cells in Example 9 were replaced with the two types of influenza A viruses described above. Fluorescence imaging of influenza A viruses with NA subtypes of N1 or N2 was performed using the positive controls compound a (BTP3-Neu5Ac) and compound c (22-002b_i) using the same materials and methods as in Example 9. The results are shown in FIG.

[0136] According to this result, it was shown that compound c (22-002b_i) performed histochemical fluorescence imaging of influenza A virus infected cells with NA subtype N1, but did not perform fluorescence imaging of influenza A virus infected cells with NA subtype N2. This revealed that the results of reactivity to influenza A virus sialidase examined in Example 10 and the results of fluorescence imaging of influenza A virus infected cells examined in this Example were consistent. These revealed that compound c (22-002b_i) is a compound capable of performing fluorescence imaging of influenza A virus with NA subtype N1, and is a compound capable of distinguishing between influenza A virus infected cells with NA subtype N1 and influenza A virus infected cells with NA subtype N2.

[0137] [Example 12] 12. Screening of compounds that detect mumps virus sialidase In this example, a derivative in which the sialic acid structure portion of BTP3-Neu5Ac, a known sialidase substrate, was modified was selected as the screening target compound. The search for a compound capable of detecting mumps virus sialidase was performed by a test for measuring the sialidase activity of mumps virus. Specifically, the search was performed by measuring the fluorescence intensity of BTP3 [(2-benzothiazol-2-yl)-4-bromophenol], a fluorescent substance generated by hydrolysis by mumps virus sialidase when mumps virus sialidase was reacted with the screening target compound. In the test, BTP3-Neu5Ac (compound a) was used as a positive control. The screening target compounds are shown in Table 4 below. BTP3-Neu5Ac of compound a was manufactured by Tokyo Chemical Industry Co., Ltd. The compounds shown in b to d and f to h in Table 4 below were synthesized in Example 1.

[0138] [Table 4]

[0139] [Measurement of mumps virus sialidase activity] The sialidase activity of mumps virus was measured by preparing mumps virus hemagglutinin-neuraminidase (HN) expressing cells that express mumps virus sialidase, and measuring the sialidase activity when each compound was added to the HN expressing cells.

[0140] HEK293T cells, which are human fetal kidney cells, were used. HEK293T cells were cultured in D-MEM medium (Dulbecco's modified essential medium) supplemented with 10% fetal bovine serum (FBS) at 37°C under 5% CO2 conditions. The plasmid used was pCAGGS-MuVHN, a plasmid in which the hemagglutinin-neuraminidase (HN) sequence of mumps virus 13V165E2 strain was incorporated into the pCAGGS vector. Compound a (positive control) and each of the compounds b to d and f to h to be screened were dissolved in DMSO to prepare a solution with a concentration of 100 mM, and stored at -30°C.

[0141] First, HEK293T cells were seeded in each well of a 6-well plate and cultured overnight at 5% CO2 and 37°C to a state of 70% confluence. According to the protocol of the transfection reagent (TransIT (registered trademark)-293 Reagent, manufactured by Takara Bio Inc.), HEK293T cells were transfected with 2.5 μg / well of the above-mentioned plasmid pCAGGS-MuVHN (derived from mumps virus: 13V165E2 strain) and cultured at 5% CO2 and 37°C for 48 hours. After removing the medium, 1 mL of PBS was added to each well, the cells were suspended, and then centrifuged (4°C, 800 × g, 10 minutes) to remove the supernatant. The cells precipitated by centrifugation were suspended in 100 mM acetate buffer (pH 4.5) to obtain a HN-expressing cell suspension.

[0142] 50 μL of the HN-expressing cell suspension prepared as described above was added to each well of a 96-well black plate and allowed to stand at 37°C for 5 minutes. Each compound was diluted to 100 μM with 100 mM acetate buffer (pH 4.5) and centrifuged (4°C, 10,000×g, 10 minutes), and 50 μL of the supernatant was added to each well and mixed with the HN-expressing cell suspension in the well (final concentration of each compound was 50 μM). After mixing, the mixture was reacted at 37°C for 20 minutes. Using a microplate reader (Infinite® M200, Tecan Japan Co., Ltd.), the fluorescence intensity of BTP3 released by reaction with sialidase was measured three times independently at an excitation wavelength of 372 nm and a measurement wavelength of 526 nm (Ex / Em=372 nm / 526 nm). Blank was the fluorescence intensity in cells transfected with the empty plasmid vector pCAGGS·MCS. Sialidase activity was measured three times independently, and the relative fluorescence intensity was calculated by subtracting the blank from the fluorescence intensity of each compound. The fluorescence intensity of the compound a (BTP3-Neu5Ac) used as a positive control was set as 100%, and the mean value ± standard error was used.

[0143] The results are shown in Figure 15. The horizontal axis of Figure 15 indicates compound No., and the vertical axis indicates relative sialidase activity. The present inventors found compound f (22-005b_c), compound d (22-002b_4), compound c (22-002b_i), and compound h (22-005b_8) as substrate compounds highly reactive to mumps virus sialidase. The sialidase activity of these compounds was about 30 to 50% of the sialidase activity of BTP3-Neu5Ac (compound a) used as a positive control, and they also had sufficient fluorescence intensity to be applicable as a virus detection reagent, particularly as a fluorescent imaging agent.

[0144] [Example 13] 13. Study of reactivity to sialidases from other virus species In Example 12, compounds f (22-005b_c), d (22-002b_4), c (22-002b_i) and h (22-005b_8) were found to be highly reactive to mumps virus sialidase and capable of detecting mumps virus sialidase. A test was carried out to confirm whether the compounds have similar reactivity to sialidases of other virus species. Specifically, cells expressing sialidases of various viruses were prepared, and the sialidase activity was measured when these compounds were added to the sialidase-expressing cells. In addition, a similar test was carried out on compounds i and j shown in the following formula as derivatives of compound h (22-005b_8). Compound i (22-005b_6) and compound j (22-005b_7) were synthesized as follows. In addition, the compounds obtained by synthesis (including intermediates) were confirmed to be the target compounds by high-resolution mass spectrometry (HRMS). High-resolution mass spectrometry was performed using an AccuTOF (JMS-T100LC) manufactured by JEOL Ltd., and was measured in positive mode by connecting an electrospray ion source (ES).

[0145] [ka]

[0146] [Synthesis of compound i (22-005b_6)] Compound i was synthesized based on the synthesis method of compound c described above in Example 1. In addition, in the formula related to the synthesis method of compound c, R in compound Ei and compound i is a pentyl group. Compound Ei was obtained using the same materials and reactions as in the synthesis method of compound c, except that caproyl chloride (137 μL) was used instead of the isobutyric anhydride used in the synthesis route of compound Ec in the synthesis method of compound c described above, and the reaction scale was halved. The obtained compound was used in the next reaction without purification. HRMS (ESI-TOF) Calcd for C 37 H 43 79 BrNO 13 S [M+H]+ : 857.15669; Found: 857.15601, Calcd for C 37 H 43 81 BrNO 13 S [M+H] + : 859.15464; Found: 859.15630.

[0147] The crude compound Ei was added to methanol (0.5 mL) and sodium methoxide solution (5 M in MeOH, 0.25 mL) in that order and stirred for 20 minutes. Sodium hydroxide solution (5 M, 0.1 mL) was then added and stirred overnight. After confirming the disappearance of the raw materials by thin layer chromatography, acetic acid (100 μL) was added to stop the reaction, and the compound i (22.9 mg) was obtained as a white powder by purification with high performance liquid chromatography. HRMS (ESI-TOF) Calcd for C 28 H 32 79 BrN2NaO9S [M+Na] + : 697.08073; Found: 697.08042, Calcd for C 28 H 32 81 BrN2NaO9S [M+Na] + : 699.07868; Found: 699.07863.

[0148] [Synthesis of compound j (22-005b_7)] Compound j was synthesized based on the synthesis method of compound c described above in Example 1. In addition, in the formula related to the synthesis method of compound c, R in compounds Ej and j is a hexyl group. Compound Ej was obtained using the same materials and reactions as in the synthesis method of compound c, except that heptanoyl chloride (155 μL) was used instead of isobutyric anhydride used in the synthesis route of compound Ec in the synthesis method of compound c described above, and the reaction scale was halved. The obtained compound was used in the next reaction without purification. HRMS (ESI-TOF) Calcd for C 38 H 4579 BrNO 13 S [M+H] + : 871.17234; Found: 871.17366, Calcd for C 38 H 45 81 BrNO 13 S [M+H] + : 873.17029; Found: 873.17027.

[0149] Half of the unpurified compound Ej was added to methanol (0.5 mL) and sodium methoxide solution (5 M in MeOH, 0.25 mL) in that order and stirred for 20 minutes. Sodium hydroxide solution (5 M, 0.1 mL) was then added and stirred overnight. After confirming the disappearance of the raw materials by thin layer chromatography, acetic acid (100 μL) was added to stop the reaction, and the compound j (13.0 mg) was obtained as a white powder by purification with high performance liquid chromatography. HRMS (ESI-TOF) Calcd for C 29 H 34 79 BrN2Na2O9S [M-H+2Na] + : 711.09638; Found: 711.09579, Calcd for C 29 H 34 81 BrN2Na2O9S [M-H+2Na] + : 713.09433; Found: 713.09398.

[0150] [Measurement of sialidase activity of various viruses] In this example, the following virus species were selected: mumps virus 13V165E2 strain, influenza A virus A / Hong Kong / 1 / 1968 H3N2 strain, human parainfluenza virus serotype 3 C243 strain, and human parainfluenza virus serotype 1 C35 strain, and these sialidase-expressing cells were prepared. Specifically, the following plasmids were used.

[0151] pCAGGS-MuVHN: A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of MuV 13V165E2 strain in the pCAGGS vector. pCAGGS-HK68NA: A plasmid containing the neuraminidase (NA) sequence of IAV A / Hong Kong / 1 / 1968 H3N2 strain in the pCAGGS vector. · pCAGGS-hPIV3HN: A plasmid that incorporates the hemagglutinin-neuraminidase (HN) sequence of hPIV3 C243 strain into the pCAGGS vector. · pCAGGS-hPIV1HN: A plasmid that incorporates the hemagglutinin-neuraminidase (HN) sequence of hPIV1 C35 strain into the pCAGGS vector.

[0152] Except for replacing the plasmid used in the sialidase activity test of Example 12 with the above-mentioned four types of plasmids, various viral sialidase expressing cells were prepared in the same manner as in Example 12. Then, using the same materials and methods as in Example 12, the sialidase activity was measured when the positive control compound a (BTP3-Neu5Ac), compound f (22-005b_c), compound d (22-002b_4), compound c (22-002b_i), compound h (22-005b_8), compound i (22-005b_6) or compound j (22-005b_7) was added to the various viral sialidase expressing cells. The test for hPIV1 sialidase was performed only for compound a (BTP3-Neu5Ac), compound h (22-005b_8), compound i (22-005b_6), and compound j (22-005b_7). Blank was the fluorescence intensity in cells transfected with the empty plasmid vector pCAGGS·MCS. Sialidase activity was expressed as the average value ± standard error of the fluorescence intensity of each compound minus Blank in three independent measurements.

[0153] The results are shown in the graph in Figure 16. The horizontal axis of each figure indicates the name of the virus from which each sialidase originates, and the vertical axis indicates sialidase activity. The white column indicates the positive control compound a (BTP3-Neu5Ac), and the black column indicates the results for each compound. According to this result, it was found that the positive control compound a (BTP3-Neu5Ac) is a sialidase substrate that reacts with sialidases of all virus species, while compound d (22-002b_4), compound h (22-005b_8), compound i (22-005b_6), and compound j (22-005b_7) are sialidase substrates that react specifically with mumps virus sialidase. Compound c (22-002b_i) was more reactive with human parainfluenza virus type 1 sialidase than with mumps virus. From this, it was revealed that compound d (22-002b_4), compound h (22-005b_8), compound i (22-005b_6) and compound j (22-005b_7) are substrate compounds with excellent specificity for mumps virus sialidase, that they are compounds that can specifically detect mumps virus sialidase and determine the presence or absence of mumps virus, and that they are compounds that produce fluorescent substances with sufficient fluorescence intensity by reacting specifically with mumps virus sialidase. Furthermore, it was found that among these compounds, compound h (22-005b_8) in particular has excellent specific detection action for mumps virus sialidase and also has excellent fluorescence intensity when detecting sialidase.

[0154] [Example 14] 14. Fluorescence imaging of mumps virus-infected cells (1) In Example 13, the compound h (22-005b_8) was used to perform fluorescence imaging of mumps virus-infected cells, which was confirmed to be capable of specifically detecting mumps virus sialidase. In addition, in order to confirm that compound h does not perform fluorescence imaging of cells infected with viruses other than mumps virus, similar tests were performed on cells infected with other viruses. In this example, the mumps virus 13V165E2 strain, influenza A virus A / Hong Kong / 1 / 1968 H3N2 strain, human parainfluenza virus serotype 1 C35 strain, and human parainfluenza virus serotype 3 C243 strain were selected as the virus species, and cells infected with these viruses were prepared.

[0155] The host cells used were MDCK cells derived from dog kidney for IAV, Vero cells derived from African green monkey kidney for MuV, and LLC-MK2 cells derived from rhesus monkey kidney for hPIV1 and hPIV3. Each cell was cultured in 5% FBS-containing MEM medium (minimum essential medium) at 5% CO2 and 37°C.

[0156] The cells were seeded in each well of a 48-well plate and cultured overnight at 5% CO2 and 37°C to a confluent state. After washing the cells with 200 μL / well of PBS, 200 μL / well of each virus-serum-free medium (Hybridoma-SFM, manufactured by Thermo Fisher Scientific Co., Ltd., hereinafter referred to as SFM) suspension was added so that each virus was 200 focus-forming units (hereinafter referred to as FFU) / well, and the cells were left to stand at 5% CO2 and 37°C for 1 hour to infect the corresponding host cells with the virus. After washing the cells with 200 μL / well of PBS, the medium was replaced with 200 μL / well of SFM and cultured at 5% CO2 and 37°C. Note that IAV- and MuV-infected cells were cultured for 24 hours, and hPIV1- and hPIV3-infected cells were cultured for 48 hours.

[0157] On the day of observation, compound a (BTP3-Neu5Ac) or compound h (22-005b_8) was diluted to 50 μM with SFM. Each compound was diluted to 100 μM as the SFM dilution solution for addition to MuV-infected cells, and SFM was prepared with 1N HCl to pH 4.5 as the SFM dilution solution for addition to hPIV1-infected cells and hPIV3-infected cells. After centrifuging (4°C, 10,000 x g, 10 minutes), the supernatant was collected and the nonspecifically cleaved fluorescent substance was separated. After washing each infected cell with 200 μL / well of PBS, 200 μL / well of SFM supernatant containing compound a or compound h was added and reacted at 37°C for 30 minutes. Each infected cell was washed with 200 μL / well of PBS, replaced with 200 μL / well of PBS, and the fluorescent image was observed using a fluorescence microscope (model number: BZ-X700, Keyence Corporation) with a BTP custom-made filter (excitation wavelength: 360 / 40 nm, absorption wavelength: 525 / 50 nm, dichroic mirror wavelength: 400 nm). The results are shown in Figure 17.

[0158] This result showed that compound h (22-005b_8) can perform histochemical fluorescent imaging of mumps virus-infected cells. In addition, the positive control compound a (BTP3-Neu5Ac) can perform fluorescent imaging of all virus-infected cells, whereas compound h (22-005b_8) performed fluorescent imaging of only mumps virus-infected cells. This demonstrated that compound h (22-005b_8) is a compound that can perform specific fluorescent imaging of mumps virus, and can specifically detect mumps virus-infected cells and distinguish the presence or absence of mumps virus.

[0159] [Example 15] 15. Screening of compounds that detect mumps virus sialidase In the above-mentioned Example 13, it was shown that compound d (22-002b_4), compound h (22-005b_8), compound i (22-005b_6) and compound j (22-005b_7) can specifically detect mumps virus. Therefore, in this Example, derivatives of these compounds, i.e., compounds in which the N-acetyl group at C5 position of the sialic acid skeleton is replaced with a linear alkyl group, were prepared and the specificity of the derivatives to mumps virus sialidase was examined. The compounds used in this examination are shown in Table 5 below. Among the compounds shown in Table 5, compounds m, n, o and p are newly prepared compounds. Compounds d, h, i and j shown in Table 5 below were synthesized in Examples 1 and 13.

[0160] [Table 5]

[0161] Compound m (22-114a_3), compound n (22-114a_5), compound o (22-114a_10) and compound p (22-114a_12) were synthesized based on the following formula. The compounds (including intermediates) obtained by synthesis were confirmed to be the target products by high-resolution mass spectrometry (HRMS). High-resolution mass spectrometry was performed using AccuTOF (JMS-T100LC) manufactured by JEOL Ltd., and was measured in positive mode by connecting an ES (electrospray ion source).

[0162] [ka]

[0163] [Synthesis of compound m (22-114a_3)] Boc2O and 4-dimethylaminopyridine (DMAP) were added to a solution of known compound X (see PLOS ONE, 2014, Vol. 9, No. 1, e81941) in tetrahydrofuran and stirred at 60°C overnight. After confirming the disappearance of the raw materials by thin layer chromatography, the mixture was allowed to cool. N,N-diethylethylenediamine was added to the reaction solution and stirred at room temperature overnight. The reaction solution was diluted with ethyl acetate, and the organic layer was washed with water (three times) and saturated saline (one time) in that order, and dried over sodium sulfate. The desiccant was filtered off, and the residue obtained by concentrating under reduced pressure was purified by silica gel column chromatography (hexane:ethyl acetate = 2:1) to obtain compound Z as a white foam. Trifluoroacetic acid (10 mL) was added to a solution of compound Z (2.45 g) in dichloromethane (10 mL) and stirred at room temperature for 1 hour. The solvent was distilled off under reduced pressure, and 1,4-dioxane and hydrochloric acid were added to the residue obtained, which was then freeze-dried to obtain compound A, which is the hydrochloride salt of the deprotected form.

[0164] Triethylamine (300 μL) was added to a THF solution of compound A (225 μmol / 2 mL), followed by the addition of propionic anhydride (120 μL) and stirring for 22 hours. The reaction solution was diluted with ethyl acetate, and the organic layer was washed once with water, once with an aqueous sodium bicarbonate solution, once with water, once with saturated saline, and then dried over sodium sulfate. The desiccant was filtered off, and the solvent was distilled off under reduced pressure to obtain a residue, to which a methanol solution of sodium methoxide (0.25 M, 4 mL) was added and stirred for 1.5 hours, after which 0.6 g of weakly acidic cation exchange resin (model number: FPC3500, Organo Corporation) was added to terminate the reaction. The resin was filtered off, and the solvent was distilled off under reduced pressure to obtain a tetraol. Methanol (1 mL), water (400 μL), and a methanol solution of sodium methoxide (5 M, 200 μL) were added in that order to the obtained tetraol (169 μmol), and the mixture was stirred for 17 hours. The mixture was neutralized with acetic acid and purified by high performance liquid chromatography to obtain the desired product (60.6 mg, 57% yield over four steps) as a colorless amorphous substance. HRMS (ESI-TOF) Calcd for C 25 H 27 79 BrN2NaO9S [M+Na] +: 633.05183; Found: 633.05009, Calcd for C 25 H 27 81 BrN2NaO9S [M+Na] + : 635.04979; Found: 635.04874.

[0165] [Synthesis of compound n (22-114a_5)] Compound n was synthesized as follows. The same materials and reactions were carried out as in the synthesis method of compound m described above, except that valeric acid chloride (100 μL) was used instead of propionic acid anhydride, to obtain the target compound n (70.9 mg, 4-step yield 64%) as a colorless amorphous substance. HRMS (ESI-TOF) Calcd for C 27 H 31 79 BrN2NaO9S [M+Na] + : 661.08313; Found: 661.08218, Calcd for C 27 H 31 81 BrN2NaO9S [M+Na] + : 663.08109; Found: 663.08082.

[0166] [Synthesis of compound o (22-114a_10)] Compound o was synthesized as follows. The same materials and reactions were carried out as in the synthesis method of compound m described above, except that capric acid chloride (170 μL) was used instead of propionic acid anhydride, to obtain the target compound o (70.9 mg, 4-step yield 64%) as a colorless amorphous substance. HRMS (ESI-TOF) Calcd for C 32 H 42 79 BrNO9S [M+H] + : 709.17944; Found: 709.17697, Calcd for C 32 H 42 81BrNO9S [M+H] + : 711.177139; Found: 711.17742, Calcd for C 32 H 41 79 BrN2NaO9S [M+Na] + : 731.16138; Found: 731.16402, Calcd for C 32 H 41 81 BrN2NaO9S [M+Na] + : 733.15934; Found: 733.15820.

[0167] [Synthesis of compound p(22-114a_12)] Compound p was synthesized as follows. The same materials and reactions were carried out as in the synthesis method of compound m described above, except that lauric acid chloride (170 μL) was used instead of propionic acid anhydride, to obtain the target compound p (25.0 mg, 4-stage yield 20%) as a colorless amorphous substance. HRMS (ESI-TOF) Calcd for C 34 H 46 79 BrNO9S [M+H] + : 737.21074; Found: 737.20932, Calcd for C 34 H 46 81 BrNO9S [M+H] + : 739.20869; Found: 739.21024, Calcd for C 34 H 45 79 BrN2NaO9S [M+Na] + : 759.19268; Found: 759.19594, Calcd for C 34 H 45 81 BrN2NaO9S [M+Na] + : 761.19064; Found: 761.19039.

[0168] [Study of reactivity of various viruses to sialidase] In the same manner as in Example 13, various viral sialidase expressing cells were prepared, and the reactivity was examined by measuring the sialidase activity when compound d (22-002b_4), compound h (22-005b_8), compound i (22-005b_6), compound j (22-005b_7), compound m (22-114a_3), compound n (22-114a_5), compound o (22-114a_10), compound p (22-114a_12) and compound a (positive control; BTP3-Neu5Ac) were added to the sialidase expressing cells. In this example, the following virus species were selected: mumps virus 13V165E2 strain, influenza A virus A / Shizuoka / 738 / 2008 H1N1 strain, influenza B virus B / Lee / 1940 strain, human parainfluenza virus serotype 1 C35 strain, and human parainfluenza virus serotype 3 C243 strain, and these sialidase-expressing cells were prepared. Specifically, the following plasmids were used.

[0169] A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of MuV 13V165E2 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IAV A / Shizuoka / 738 / 2008 H1N1 strain in the pCAGGS vector A plasmid containing the neuraminidase (NA) sequence of IBV B / Lee / 1940 strain in the pCAGGS vector A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of hPIV1 C35 strain in the pCAGGS vector A plasmid containing the hemagglutinin-neuraminidase (HN) sequence of hPIV3 C243 strain in the pCAGGS vector

[0170] HEK293T cells, which are human fetal kidney cells, were used. HEK293T cells were cultured in D-MEM (Dulbecco's modified essential medium) supplemented with 10% fetal bovine serum (FBS) at 37°C under 5% CO2 conditions. First, 7.5 × 10 HEK293T cells were placed in each well of a 6-well plate. 5 The cells were seeded at 1000 x 1000 cells / well and cultured overnight at 5% CO2 and 37°C to a confluent state of 80-90%. According to the protocol of the transfection reagent (TransIT (registered trademark)-293 Reagent, manufactured by Takara Bio Inc.), HEK293T cells were transfected with 2.5 μg / well of each of the above-mentioned plasmids and cultured at 5% CO2 and 37°C for 72 hours. After removing the medium, 1 mL of phosphate buffer (131 mM NaCl, 14 mM Na2HPO4, 1.5 mM KH2PO4, 2.7 mM KCl, pH 7.2, hereinafter referred to as PBS) was added to each well, the cells were suspended, and the supernatant was removed by centrifugation (4°C, 1000 x g, 10 minutes). The cells precipitated by centrifugation were suspended in 100 mM acetate buffer (pH 6.0 when the sialidase to be measured was IAV or IBV, and pH 4.5 when the sialidase was MuV, hPIV1, or hPIV3) to prepare NA-expressing cell suspensions for each virus species.

[0171] Each compound was dissolved in DMSO in advance to a stock solution of 100 mM, and diluted to a concentration of 1 mM with 100 mM acetate buffer (pH 6.0 when the sialidase to be measured is IAV or IBV, pH 4.5 when it is MuV, hPIV1 or hPIV3). After centrifugation (4°C, 10,000×g, 10 minutes), the supernatant was collected and serially diluted so that the final concentration of the compound to be added was 25 μM, 50 μM, 100 μM and 200 μM. 40 μL of the NA-expressing cell suspension prepared as described above and 10 μL of the compound dilution solution (final concentration of compound: 25 μM, 50 μM, 100 μM and 200 μM) were added to each well of a 96-well black plate on ice, and the mixture was mixed on a plate mixer for 5 seconds, and then reacted at 37°C for 20 minutes. After the reaction was completed, 100 mM sodium carbonate buffer (pH 10.7) was added at 50 μL / well on ice. The fluorescence intensity of BTP3 released by the reaction with sialidase was measured three times independently using a microplate reader (Infinite® M200, Tecan Japan Co., Ltd.) at an excitation wavelength of 372 nm and a measurement wavelength of 526 nm (Ex / Em = 372 nm / 526 nm). The blank was the fluorescence intensity in cells transfected with the empty plasmid vector pCAGGS·MCS. Sialidase activity was expressed as the mean value ± standard error of the fluorescence intensity of each compound minus the blank in three independent measurements.

[0172] The results are shown in the graphs of Figures 18 to 20. The vertical axis of each graph is the fluorescence intensity indicating the sialidase activity, and the horizontal axis is the final concentration (μM) of the compound added. These results revealed that, among the compounds in which the N-acetyl group at the C5 position of the sialic acid skeleton is a linear alkyl group, the reactivity to mumps virus sialidase changes depending on the carbon number of the linear alkyl group (Figure 18(a)). More specifically, as shown in Figure 18(a), the reactivity to mumps virus sialidase tended to decrease as the carbon number of the linear alkyl group at the C5 position of the compound increased (compound m has 3 carbon atoms, compound d has 4 carbon atoms, compound n has 5 carbon atoms, compound i has 6 carbon atoms, compound j has 7 carbon atoms, compound h has 8 carbon atoms, compound o has 10 carbon atoms, and compound p has 12 carbon atoms), but the reactivity increased in compound h (22-005b_8) with 8 carbon atoms. In addition, as shown in Figure 18(b), Figure 19, and Figure 20, compound m (22-114a_3: carbon number 3) showed high reactivity with all the virus sialidases. From these results, it was revealed that compounds with 4 to 10 carbon atoms in the linear alkyl group at the C5 position of the compound are substrate compounds having specificity for mumps virus sialidase, and among these, compounds with 5 to 10 carbon atoms in the linear alkyl group at the C5 position of the compound, i.e., compound n (22-114a_5), compound i (22-005b_6), compound j (22-005b_7), compound h (22-005b_8), and compound o (22-114a_10) are substrate compounds having particularly excellent specificity, and are compounds that can specifically detect mumps virus sialidase and distinguish the presence or absence of mumps virus. Furthermore, these compounds with a linear alkyl group having 5 to 10 carbon atoms at the C5 position react specifically with mumps virus sialidase to produce fluorescent substances with sufficient fluorescence intensity, demonstrating that they are excellent in terms of the specific detection activity for mumps virus sialidase as well as in terms of the fluorescence intensity when detecting sialidase.

[0173] [Example 16] 16. Fluorescence imaging of mumps virus-infected cells (2) In Example 15, the compounds having 4 to 10 carbon atoms in the C5-position linear alkyl group, Compound d (22-002b_4), Compound n (22-114a_5), Compound i (22-005b_6), Compound j (22-005b_7), Compound h (22-005b_8), and Compound o (22-114a_10), which were confirmed to be capable of detecting mumps virus sialidase, were used to perform fluorescence imaging of mumps virus-infected cells. In addition, to confirm that these compounds do not perform fluorescence imaging on cells infected with viruses other than mumps virus, similar tests were performed on cells infected with other viruses. In this example, the mumps virus 13V165E2 strain, influenza A virus A / Shizuoka / 738 / 2008 H1N1 strain, influenza B virus B / Lee / 1940 strain, human parainfluenza virus serotype 1 C35 strain, and human parainfluenza virus serotype 3 C243 strain were selected as the virus species, and cells infected with these viruses were prepared.

[0174] The host cells used were African green monkey kidney-derived Vero cells for MuV, canine kidney-derived MDCK cells for IAV and IBV, and rhesus monkey kidney-derived LLC-MK2 cells for hPIV1 and hPIV3. Each cell was cultured in 5% FBS-containing MEM medium (minimum essential medium) at 5% CO2 and 37°C.

[0175] Cells were plated at 2 x 10 in each well of a 96-well plate. 4The cells were seeded at 100 μL / well so that each virus was 100 focus-forming units (FFU) / well, and then cultured at 5% CO2 and 37°C overnight to reach a confluent state. After washing the cells with 50 μL / well of PBS, 50 μL / well of each virus-serum-free medium (Hybridoma-SFM, manufactured by Thermo Fisher Scientific Co., Ltd., hereinafter referred to as SFM) was added, and the cells were left to stand at 5% CO2 and 37°C for 1 hour to infect the corresponding host cells with the virus. After washing the cells with 50 μL / well of PBS, the medium was replaced with 50 μL / well of SFM and cultured at 5% CO2 and 37°C. Note that IAV- and IBV-infected cells were cultured for 24 hours, and MuV-, hPIV1- and hPIV3-infected cells were cultured for 48 hours.

[0176] Just before observation, the positive control compound a (BTP3-Neu5Ac) or each compound was diluted to 200 μM with SFM (pH 7.4). As the SFM dilution solution to be added to the hPIV1-infected cells and hPIV3-infected cells, SFM was prepared with 1N HCl to pH 4.5 for use. After centrifugation (4°C, 10,000×g, 10 minutes), the supernatant was collected and the nonspecifically cleaved fluorescent substance was separated. The SFM on each infected cell was removed on ice and replaced with SFM supernatant containing 200 μM of each compound, and reacted at 37°C for 20 minutes. At the end of the reaction, the SFM supernatant containing each compound was removed on ice, and each infected cell was washed with 50 μL / well of PBS and then replaced with 50 μL / well of SFM. Fluorescence images were observed using a fluorescence microscope (model number: BZ-X700, manufactured by Keyence Corporation) with a custom-made BTP filter (excitation wavelength: 360 / 40 nm, absorption wavelength: 525 / 50 nm, dichroic mirror wavelength: 400 nm) (objective lens 20x, shooting settings: high sensitivity mode, exposure time 1 / 4 seconds). The results are shown in Figures 21 to 23.

[0177] According to the results, it was shown that the compounds having 4 to 10 carbon atoms in the C5-position linear alkyl group, Compound d (22-002b_4), Compound n (22-114a_5), Compound i (22-005b_6), Compound j (22-005b_7), Compound h (22-005b_8) and Compound o (22-114a_10), can perform histochemical fluorescence imaging of mumps virus-infected cells (Figure 21(a)). Of these, Compound d (22-002b_4), which has 4 carbon atoms, was found to show slight fluorescence in hPIV3 and hPIV1-infected cells. On the other hand, the compounds having 5 to 10 carbon atoms in the C5-position linear alkyl group performed fluorescence imaging of only mumps virus-infected cells. From this, it was revealed that the compounds having a carbon number of 5 to 10 in the linear alkyl group at the C5 position, i.e., compound n (22-114a_5), compound i (22-005b_6), compound j (22-005b_7), compound h (22-005b_8) and compound o (22-114a_10), are compounds capable of specifically fluorescent imaging of the mumps virus, and are compounds capable of specifically detecting mumps virus-infected cells and determining the presence or absence of the mumps virus.

[0178] [Example 17] 17. Fluorescence imaging of mumps virus-infected cells (3) In this example, we investigated whether compounds with a linear alkyl group at C5 of 4 to 10 carbon atoms (compounds d, n, i, j, h, and o) could be used for fluorescent imaging of mumps virus strains different from those used in the above examples. In this example, mumps virus 13V165E2 strain (strain isolated at Shizuoka City Environmental Health Research Institute in 2013), mumps virus Torii strain (ATCC VR-1880; strain isolated in Japan in 1969), and mumps virus lowa.US / 2006 strain (ATCC VR-1899; strain isolated in Iowa, USA in 2006) were selected as virus species, and cells infected with these viruses were prepared.

[0179] Mumps virus-infected cells were prepared in the same manner as in Example 16, except that the virus used in the preparation of virus-infected cells in Example 16 was replaced with the three types of mumps virus described above. Fluorescence imaging of mumps virus using each compound was performed using the same materials and methods as in Example 16. The results are shown in Figure 24.

[0180] These results show that compounds having a linear alkyl group at the C5 position with 4 to 10 carbon atoms, namely compound d (22-002b_4), compound n (22-114a_5), compound i (22-005b_6), compound j (22-005b_7), compound h (22-005b_8) and compound o (22-114a_10), can be used for histochemical fluorescent imaging of cells infected with the 13V165E2, Torii and lowa strains of mumps virus. From these findings, it was found that compound d (22-002b_4), compound n (22-114a_5), compound i (22-005b_6), compound j (22-005b_7), compound h (22-005b_8) and compound o (22-114a_10) are capable of fluorescent imaging of mumps virus, regardless of the mumps virus strain.

[0181] The present invention is not limited to the above-described embodiments or examples, and the technical scope of the present invention includes various modified forms of design within the scope that does not deviate from the gist of the invention described in the claims. [Industrial Applicability]

[0182] INDUSTRIAL APPLICABILITY The present invention provides a virus detection reagent and a virus detection method using the same, and is widely useful in industries in the fields of virus research, virus diagnosis, medical care, etc.

Claims

1. A compound represented by the following formula (I), formula (II) or formula (III), or a salt thereof, or a solvate thereof: 【Chemistry 1】 [In formula (II), R 1 represents a linear alkyl group having 3 to 9 carbon atoms or an isopropyl group.

2. A reagent for detecting a virus having sialidase activity or a viral sialidase, comprising: A detection reagent comprising a compound represented by the following formula (I), formula (II) or formula (III), or a salt thereof, or a solvate thereof: 【Chemistry 2】 [In formula (II), R 1 represents a linear alkyl group having 3 to 9 carbon atoms or an isopropyl group.

3. the virus is an influenza virus, The compound represented by the formula (I), the formula (II) or the formula (III), or a salt thereof, or a solvate thereof, 1 The detection reagent according to claim 2 , wherein is an isopropyl group.

4. the virus is an influenza A virus, The detection reagent according to claim 2, comprising a compound represented by formula (I) or a salt thereof, or a solvate thereof.

5. the virus is an influenza A virus of NA subtype N1, The compound represented by the formula (II) or a salt thereof, or a solvate thereof is contained, and R 1 The detection reagent according to claim 2 , wherein is an isopropyl group.

6. the viruses are influenza A virus and influenza B virus, The detection reagent according to claim 2, comprising the compound represented by formula (III) or a salt thereof, or a solvate thereof.

7. A method for detecting influenza virus, comprising: Adding the detection reagent according to claim 3 to a specimen; and A detection method comprising determining the presence or absence of influenza virus based on the fluorescent substance produced by the above process.

8. A method for detecting influenza virus, comprising: A detection method comprising fluorescent imaging of influenza virus-infected cells using the detection reagent according to claim 3.

9. the virus is a mumps virus, The compound represented by the formula (II) or a salt thereof, or a solvate thereof is contained, and R 1 The detection reagent according to claim 2, wherein is a linear alkyl group having 3 to 9 carbon atoms.

10. the virus is a mumps virus, The compound represented by the formula (II) or a salt thereof, or a solvate thereof is contained, and R 1 The detection reagent according to claim 2 , wherein is a heptyl group.

11. A method for detecting mumps virus, comprising: Adding the detection reagent according to claim 9 or 10 to a specimen; and A detection method characterized by determining the presence or absence of mumps virus based on the fluorescent substance produced by the above process.

12. A method for detecting mumps virus, comprising: A detection method comprising fluorescent imaging of mumps virus-infected cells using the detection reagent according to claim 9 or 10.

Citation Information

Patent Citations

  • Optical integrated element

    JP1989093964A